Immuron Limited
Annual Report 2017

Plain-text annual report

Immuron Limited ABN 80 063 114 045 Annual report for the year ended 30 June 2017 Immuron Limited ABN 80 063 114 045 Annual report - 30 June 2017 Contents Corporate directory Intellectual property report Directors' report Financial statements Consolidated statement of profit or loss and other comprehensive income Consolidated statement of financial position Consolidated statement of changes in equity Consolidated statement of cash flows Notes to the consolidated financial statements Directors' declaration Independent auditor's report to the members Shareholder information Page 1 7 9 31 32 33 34 35 72 73 78 Directors Secretary Interim Chief Executive Officer Registered Office Principal Place of Business Share Registry - Australia Share registry - United States Auditor - Australia Auditor - United States Immuron Limited Corporate directory Dr. Roger Aston Independent non-executive chairman Mr. Peter Anastasiou Executive vice chairman Mr. Daniel Pollock Independent non-executive director Mr. Stephen Anastasiou Independent non-executive director Prof. Ravi Savarirayan (appointed 7 April 2017) Independent non-executive director Mr. Phillip Hains Mr. Peter Vaughan Dr. Jerry Kanellos Level 3, 62 Lygon Street Carlton VIC 3053 Australia Telephone: +61(0)3 9824 5254 Facsimile: +61(0)3 9822 7735 Unit 10, 25 - 37 Chapman Street Blackburn North VIC 3130 Australia Telephone: +61 (0)3 9824 5254 Facsimile: +61 (0)3 9822 7735 Security Transfer Registrars Pty Ltd 770 Canning Highway Applecross WA 6153 Australia Telephone: +61 (0)8 9315 2333 Facsimile: +61 (0)8 9315 2233 Bank of New York 225 Liberty Street New York, NY 102286 United States of America Telephone: +1 212 495 1784 William Buck Level 20 181 William Street Melbourne VIC 3000 Australia +61 (0)3 9824 8555 Marcum LLP 1600 Market Street 32nd Floor, Philadelphia PA 19103 United States of America Telephone: +1 215 297 2524 1 Solicitors - Australia Solicitors - United States Bankers Immuron Limited Corporate directory (continued) Francis Abourizk Lightowlers (FAL) Level 16 356 Collins Street Melbourne VIC 3000 Australia +61 (0)3 9642 2252 Carter Ledyard and Milburn LLP 2 Wall Street New York NY 10005 United States of America Telephone: +1 212 238 8605 National Australia Bank (NAB) 330 Collins Street Melbourne VIC 3000 Australia Securities exchange listings Websites Australian Securities Exchange (Code: IMC) NASDAQ Exchange (Code: IMRN) www.Immuron.com www.travelan.com.au 2 Dear Shareholders, Highlights • Fatty liver trials are on track and top-line results expected Q4 2017 for NASH, Q4 2018 for Pediatric NAFLD and Q1 2019 for ASH Immuron Limited 30 June 2017 Paediatric NAFALD Phase II trial recruits first patient • NASDAQ Listing raises US$6 million • NASDAQ Phase II Study achieves major milestones and receives new US stimulus • • Clostridium difficile infection trial clinical drug manufactured, ethics and regulatory approvals and site initiated • • US Department of Defence Research Collaboration expands • IMM-124E progresses to next study phase in acute colitis model Travelan marketing strategy drives sales growth Fatty Liver Portfolio - Three Ongoing Phase II Programs in Clinical Development (NASH, ASH and Pediatric NAFLD) The lead Principle Investigator for the Immuron non-alcoholic steatohepatitis (NASH) clinical study Dr Arun Sanyal, is the former President of AASLD (American Association for the Study of Liver Diseases) and current Chair of the Liver Study Section at the National Institute of Health (NIH). The study achieved its recruitment goal of at least 120 patients this year and successfully enrolled 133 patients with biopsy proven NASH. The primary endpoint is changes in liver fat content confirmed by MRI and secondary endpoints being changes in ALT (liver enzymes). The top-line results for the study are expected to be reported by Q4 2017. NASH is a severe form of non-alcoholic fatty liver disease (NAFLD). It affects about 16 million people annually in the United States alone, making it a prime opportunity for the pharmaceutical and biotechnology industries. With 17.3 percent of Americans aged 15 - 19 suffering NAFLD, Immuron’s Phase I/II clinical trial with Emory University is timely. Health authorities estimate paediatric NAFLD affects five to 10 percent of the US paediatric population, with no current approved treatments. The lead Principle Investigator for our Pediatric NAFLD study is Dr Miriam Vos, Emory University. Dr Vos specializes in the treatment of gastrointestinal disease in children as well as fatty liver disease and obesity. Our NIH funded Phase II double blind, placebo control, randomized clinical study of IMM-124E enrolled the first patient into the study in February this year and has so far randomized over 10% of the targeted 40 patients into the study. The primary endpoint is changes in ALT (liver enzymes) following 3 months of treatment with top-line results expected in Q4 2018. Dr Arun Sanyal is also the lead Principle Investigator of the Immuron alcoholic steatohepatitis (ASH) clinical study which is also funded by the NIH. Over 50% of the targeted 66 patients have been randomized into the study. The primary endpoint is changes in ALT (liver enzymes) with top-line results are expected in Q1 2019. US Securities and Exchange Commission Registration Immuron successfully completed its Initial Public Offering (IPO) on 9 June 2017. The Company, through its lead broker Joseph Gunnar & Co. LLC and Rodman & Renshaw placed 610,000 ADSs and 701,500 Warrants raising USD$6.1M before costs. The close of this raising marked a significant milestone in Immuron’s lifecycle as the Company not only secured additional funding to process its clinical portfolio and current primary clinical trial to completion, but it also gained international exposure to the much large US market. The listing process had been an ongoing process of audit, legal and regulatory reviews for a number of months to ensure Immuron’s compliance with SEC and NASDAQ regulations. 3 Immuron Limited 30 June 2017 (continued) NASH Clinical Trial Achieves Major Milestones and Receive New US Stimulus The Company reported the results of the planned interim analysis in July this year. The primary objective of the interim analysis was to evaluate the safety of IMM-124E. The interim analysis was conducted by an Independent Committee to maintain blindness of both company and investigators as required to maintain the study integrity. The Committee also explored the data for signals of efficacy from the primary, secondary and exploratory end points. The analysis was not powered for efficacy due to the limited sample size. The report submitted to the Company by the Committee confirmed that there were no safety concerns or adverse events, serum biochemistry, hematology, vital signs, or physical examination findings for both treatment groups. We were very pleased to be able to report the efficacy signals on liver enzymes (ALT and AST) which demonstrated a dose related reduction in both treatment doses at 24 weeks, though not statistically different than placebo. As these parameters inherently fluctuate over time and are significantly affected by baseline values the interim analysis committee also had scheduled to perform additional analyses on the data set to correct for these inherent variations. Comparing the Area Under Curve for the ALT/AST data over time of IMM-124E to Placebo, accounts for all the available data. Such analysis demonstrated a significant reduction of ALT and AST over time (AUC ANCOVA analysis) compared to placebo. A dose-related effect was reported when the greatest decrease occurred in the highest dose group, with the low dose group decreasing by an intermediate amount compared with the placebo group. The Company believes that this documented effect, together with a correlation between ALT and AST, is the proof of concept for a biological effect demonstrating decrease in liver injury. Immuron has also advanced its world-leading IMM-124E research in NASH with two new studies at Duke IMM-124E’s unique University and Sanyal Biotechnology. The studies should augment mechanism of action (MOA) and expected effect on NASH. The results from these studies will supplement our pre-clinical and clinical studies to date, including the anti-fibrotic effect seen in the CCl4 model and the metabolic and immunological improvements seen in both the Ob-Ob mice as well as the Company's phase I clinical study. the evidence of The studies will attempt to generate comparable results in the two leading NASH mouse models which mimic the full clinical spectrum of human NASH, from simple steatosis to substantial fibrosis and cirrhosis. The additional preclinical studies will proceed under the leadership of two internationally renowned NASH researchers, Dr Arun Sanyal, founder of Sanyal Biotechnology, and Dr Anna-Mae Diehl, Director at the Duke University Liver Centre. The studies are ongoing and are expected to be completed by Q4 2017. Clostridium Difficile Infection (CDI) Trial Drug Completes Manufacturing Phase Immuron is pursuing the biopharmaceutical research and development for an effective and safe non-antibiotic treatment of CDI which accounts for more than 450,000 patients and over 29,000 deaths per year in the United States alone. The IMM-529 drug product for the study has been manufactured and is a first-in class oral immunotherapeutic targeting the treatment of Clostridium difficile infection. IMM-529 has been shown in pre-clinical tests to be an effective treatment in all phases of the disease and success in this trial will provide encouragement to the Board and Management that the IMM-529 drug product has significant potential for continued clinical development. The Company received approval from the Israeli Ministry of Health (MoH) and the Hadassah Medical Center Ethics Committee in August of this year to perform Immuron's IMM-529 clinical study. Immuron has completed the site initiation and the site is open for enrolment. The first of 60 patients is scheduled to be randomized by end of September 2017. The Phase I/II randomized, double-blind, placebo-control clinical study is designed to evaluate the safety and preliminary efficacy of Immuron’s IMM-529 drug product for the treatment of CDI. 4 Immuron Limited 30 June 2017 (continued) Clostridium Difficile Infection (CDI) Trial Drug Completes Manufacturing Phase (continued) Eligible patients will be randomized, in addition to their standard of care treatment, to receive either IMM-529 or placebo three times daily for a total of 28 days which will then be followed by two months of monitoring for any recurrence of disease. The primary objective of the study is to assess IMM-529's patient safety and tolerability, while secondary endpoints will evaluate the preliminary efficacy of the product evaluated by duration and severity of symptoms, and the rate of recurrence. Top-line results are anticipated in the fourth quarter of 2018. The clinical study will be conducted under the leadership of Professor Yoseph Caraco, who is the head of the Clinical Pharmacology Unit at Hadassah Medical Center in Jerusalem, which specializes in early stage clinical studies. The protocol for the study was jointly developed by Immuron with Professor Caraco, Professor Allon Moses, Chairman of the Department of Clinical Microbiology and Infectious Diseases, and Professor Jacob Strahilevitz of the Department of Clinical Microbiology and Infectious Diseases at Hadassah. Travelan Marketing Strategy Drives Sales Growth Sales of Immuron’s flagship OTC travellers’ diarrhea treatment Travelan, enjoyed a strong 38 percent increase in sales compared to the same period last year. May 2017 saw Travelan’s highest ever monthly sales in the US, reinforcing month-on-month revenue hikes. Much of the growth has come through our excellent partnership in the travel industry with Passport Health. Our marketing strategy includes staff education in over 3,000 pharmacies, boosted point-of-sale advertising, closer relations with distributors and brokers, and better shelf positions. We also sponsored a satellite symposium at the 15th Conference of the International Society of Travel Medicine (CISTM15). The symposium, on the overuse of antibiotics in travellers’ diarrhea, featured three renowned gastrointestinal experts and helped gain us exposure to more than 1,500 health professionals from 60 countries. Collaboration with the US Department of Defence Expands Immuron this year announced that it will expand the current scope of the cooperative research and development agreement executed in June 2016 with the Walter Reed Army Institute of Research (WRAIR), Silver Spring MD, USA. The Company also executed a cooperative research and development agreement with the Navel Medical Research Centre in August 2016. The current agreement will be expanded to include the development of three fluoroquinolone-resistant Shigella specific anti-microbial therapeutics for pre-clinical evaluation. WRAIR will fund the evaluation of the anti-Shigella specific activity of our new antibodies, including assessing their protective capacity in established mouse and guinea pig small animal models. Joining the development program and expanding the scope of the program even further, will be the Armed Forces Research Institute of Medical Sciences (AFRIMS), headquartered in Bangkok, Thailand. AFRIMS will fund and perform the evaluation of these 3 Shigella specific therapeutics in Non-Human primate (NHP) clinical studies which results in the full clinical spectrum of the disease as seen in humans. The proposed work will be initiated once efficacy is proven in the small animal studies. Shigella is a highly virulent pathogenic organism that can cause disease in humans at extremely low infectious doses. Exposure to as little as 10 to 100 bacteria can cause disease and therefore Shigella can spread easily from person to person. Infection in humans is characterised by the ability of Shigella to invade the mucosal epithelium, replicate intracellularly and spread intercellularly. Animal models that mimic the disease in humans are essential tools for studying Shigella pathogenesis and product efficacy. The World Health Organisation (W.H.O.) has identified shigella as one of 12 families of bacteria that pose the greatest threat to human health. It estimates shigella causes about 165 million cases of dysentery a year, and kills more than a million people, mostly children in the developing world. 5 Immuron Limited 30 June 2017 (continued) IMM-124E Progresses to Next Study Phase in Acute Colitis Model Successful completion of stage one of the three stage IMM-124E colitis pre-clinical program has validated continuation of the research. Conducted at the University of Zurich under the leadership of the renowned Professor Gerhard Rogler, the preclinical research data showed a beneficial biological effect of IMM-124E within the model. Professor Rogler is a leader in the field of Colitis and has authored more than 200 original peer reviewed articles. Colitis, mostly identified with ulcerative colitis and Crohn’s disease, is a group of chronic and generally debilitating inflammatory bowel diseases affecting millions of people globally. The market for inflammatory bowel disease therapeutics could reach US$10 billion annually by 2021. New Director Appointed In April, we announced the appointment of Professor Ravi Savarirayan as a Director. Professor Savarirayan is a consultant clinical geneticist at the Victorian Clinical Genetics Services. He is a certified specialist in clinical genetics and a fellow of the Royal Australasian College of Physicians who has published more than 150 peer-reviewed articles, sits on the editorial boards of four internationally distinguished medical journals and holds, or has held prominent office in several important international medical societies. Dr. Jerry Kenellos Interim Chief Executive Officer (CEO) Immuron Limited Melbourne 28 September 2017 6 Immuron Limited Intellectual property report 30 June 2017 Intellectual property report Immuron owns a number of patent families that have been filed to protect both the vaccine that is used to generate Immuron’s colostrum enriched with antibodies of choice, as well as methods of treating certain conditions with the resulting hyper-immune colostrum. Immuron’s patent rights are supplemented by a comprehensive body of confidential and proprietary expertise that has been developed over many years and relates to the methods of production of the hyper-immune colostrum. These trade secrets include information relating to a low cost production system and an effective immunisation process that is approved by an independent animal ethics committee. During the year ended 30 June 2017, Immuron continued to progress its patent portfolio and has successfully prosecuted patents to Grant, over various global jurisdictions. A summary of the principal patent families owned by Immuron is set out in the table below: Number Country Status Expiry Australia Canada Europe New Zealand USA Granted Pending Accepted Pending Pending Granted Granted Granted Granted Australia Brazil Canada China Europe India New Zealand USA USA 4 March 2024 4 March 2024 4 March 2024 4 March 2024 4 March 2024 4 March 2024 4 March 2024 4 March 2024 25 February 2028 Travelan: Composition and Method for the Treatment and Prevention of Enteric Bacterial Infections 2004216920 0408085-8 2,517,911 201210055406.0 EP 1605975 230664 B 542088 9,402,902 8,637,025 Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders 2009222965 2,718,381 EP 2268669 587901 13/715,371 Method and Apparatus for the Collection of Fluids 2,527,260 2004244673 544198 Anti LPS Enriched Immunoglobulin Preparation for use in Treatment and/or Prophylaxis of a Pathologic Disorder 2010243205 2760096 13/265,252 2424890 12103554.8 315924 5740390 10-2011-7027634 335793 201171304 27 April 2030 27 April 2030 27 April 2030 27 April 2030 27 April 2030 27 April 2030 27 April 2030 27 April 2030 27 April 2030 27 April 2030 Australia Canada USA Europe Hong Kong Israel Japan Korea Mexico Eurasia Granted Pending Pending Pending Published Pending Granted Accepted Pending Pending 11 March 2029 11 March 2029 11 March 2029 11 March 2029 11 March 2029 Granted Pending Granted Granted Pending 10 June 2024 10 June 2024 10 June 2024 Canada Australia New Zealand Granted Granted Granted 7 Number Country Status Expiry Immuron Limited Intellectual property report 30 June 2017 (continued) Australia Canada Europe USA Hong Kong Anti LPS Enriched Immunoglobulin Preparation for use in Treatment and/or Prophylaxis of a Pathologic Disorder 2011290478 2808361 2605791 13/817,414 1185016 Methods and Compositions for the Treatment and/or Prophylaxis of Clostridium Difficile Associated Disease 2014253685 2,909,636 2986316 14/785,527 201480034857.3 713233 17 April 2034 17 April 2034 17 April 2034 17 April 2034 17 April 2034 17 April 2034 Australia Canada Europe USA China New Zealand 27 April 2030 27 April 2030 27 April 2030 27 April 2030 27 April 2030 Pending Pending Pending Pending Pending Pending Granted Pending Pending Pending Published 8 Immuron Limited Directors' report 30 June 2017 Your Directors present their report on the consolidated entity consisting of Immuron Limited and the entities it controlled at the end of, or during, the year ended 30 June 2017. Throughout the report, the consolidated entity is referred to as the Company. Directors The following persons held office as Directors of Immuron Limited during the financial year: Dr. Roger Aston, Independent non-executive chairman Mr. Peter Anastasiou, Executive vice chairman Mr. Daniel Pollock, Independent non-executive director Mr. Stephen Anastasiou, Independent non-executive director Prof. Ravi Savarirayan, Independent non-executive director (appointed 7 April 2017) The following persons held office as Key Management Personnel of Immuron Limited during the financial year with the following changes subsequent to 30 June 2017: Dr. Jerry Kenellos, Interim Chief Executive Officer (CEO) (appointed 3 August 2017) and Chief Operating & Scientific Officer (COSO) Mr. Thomas Liquard, Chief Executive Officer (CEO) (ceased 3 August 2017) Principal activities The Company's principal activity is a product development driven biopharmaceutical Company focused on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. Dividends No dividends have been paid during the financial year. The Directors do not recommend that a dividend be paid in respect of the financial year (2016: $nil). Operating and financial review Consolidated statement of profit or loss and other comprehensive income The reported after tax loss of $6,804,154 is after fully expensing all of the Company’s research and development expenditure and patenting costs of $4,630,674 incurred during the year. The Company has engaged a specialised R&D Tax consultant to review the research and development expenses of the Company for financial year 2017, to ensure the maximum rebate is received under the Australian Government’s R&D Tax Incentive program. It is anticipated that the Company will receive substantial cash inflows following this review process. The total operating revenue for the year was $1,396,197, which is an increase of 39% from financial year 2016. Gross Profit increased 5.8% to $1,058,651 compared to 2016. Consolidated statement of financial position At 30 June 2017 the Company’s cash position was $3,994,924 (30 June 2016: $2,290,639). The Company had trade and other receivables of $1,768,237 (30 June 2016: $4,387,772). This receivables amount includes future receivables from the Australian Government under the R&D Tax Incentive program mentioned above. The Company entered into a short-term funding arrangement as a cash advance with Grandlodge Capital Pty Ltd, an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou, against the anticipated refund Immuron will the Research and Development Income Tax Concession Incentive for the Company's eligible R&D expenditure. All drawdowns have been repaid. Please refer to Related Party disclosure note. receive from the Australian Taxation Office under 9 Immuron Limited Directors' report 30 June 2017 (continued) Operating and financial review (continued) Consolidated statement of financial position (continued) As announced to the market on 17 February 2016, the Company secured $1,700,000 in funding with a New York-based Investment Fund. This facility is being used to fund the immediate start of the clinical phase for IMM-529 in Costridium difficile which recently completed a very successful pre-clinical program. The investment was structured in three tranches as disclosed to the market. No additional tranches or funding was received under this agreement during financial year 2017. Immuron Limited has processed all repayments based on agreed terms. Consolidated statement of cash flows The net operating and investing cash outflows for the year were $7,031,088 (2016: $5,158,336) which included costs associated with the Company’s further development of its research and development programs, together with significant clinical trial cost expenditure associated with the NASH and ASH clinical trials. During the financial year $1,615,043 was received from the Australian Government’s R&D tax concession refund incentives associated with eligible research and development expenditure and activities. The Company will continue to take advantage of the available Australian Government Research and Development incentives available. Material business risks Immuron develops therapeutics and has projects in both the commercial sales and development phases. Any investment in the development of therapeutics is considered high‐risk. The Company is also subject to risks associated with the usual conduct of business and these risks, including interest rate movements, labour conditions, government policies, securities market conditions, exchange rate fluctuations, and a range of other factors which are outside the control of the Board and Management. More specific material risks of the sector and the Company include, but are not limited to: • Scientific, technical and clinical - the outcome of the development of therapeutics is inherently unknown. Activities are experimental in nature so the risk of failure or delay is material. Key development activities, including clinical trials and product manufacture, are undertaken by specialist contract organisations; and there are risks in managing the quality and timelines of these activities. • Regulatory - products and their testing, may not be approved by, or be delayed by regulatory bodies (as was the case in Canada) whose approvals are necessary before products can be sold in market. • • Financial - the Company currently, and since inception, does not receive sufficient income to cover operating expenses. The Company may require additional capital funding in the future, and no assurance can be given that such funding will be available, if required. - commercial success requires the ability to develop, obtain and maintain Intellectual Property (IP) commercially valuable patents and, trade secrets. Gaining and maintaining the IP across multiple countries; and preventing the infringement of the Company’s exclusive rights involves management of complex legal, scientific and factual issues. The Company must also operate without infringing upon the IP of others. • Commercialisation - the Company relies, and intends to rely, upon corporate partners to market, and in some cases finalise development of its products, on its behalf. There are risks in establishing and maintaining these relationships, and with the manner in which partners execute on these collaborative agreements. • • • Product acceptance and competitiveness - a developed product may not be considered by key opinion leaders (eg. doctors), reimbursement authorities (eg. PBA-listing) or the end customer to be an effective alternative to products already on market, or new superior future products may be preferred. liability - a claim or product recall would significantly impact Product Insurance, at an acceptable cost, may not be available or be adequate to cover liability claims if a marketed product is found to be unsafe. the Company. Key personnel - the Company’s success and achievements against timelines depend on key members of its highly qualified, specialised and experienced management and scientific teams. The ability to retain and attract such personnel is important. 10 Immuron Limited Directors' report 30 June 2017 (continued) Material business risks (continued) • Grant and R&D incentives - the Company may undertake R&D activities under competitive grants and be part-funded by other incentive programs (eg R&D tax credits). There is no certainty that grants or incentive programs will continue to be available to the Company, and changes in government policy may reduce their applicability. In accordance with good business practice in the pharmaceutical industry the company’s management actively and routinely employs a variety of risk management strategies. These are broadly described in the Corporate Governance Statement. Biotechnology companies - inherent risks Some of the risks inherent in the development of a pharmaceutical product to a marketable stage include the uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development or may infringe intellectual property rights of other parties, the obtaining of the necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Also a particular compound may fail the clinical development process through lack of efficacy or safety. Companies such as Immuron Limited are dependent on the success of their R&D projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in these areas must be regarded as speculative, taking into account these considerations. This Report may contain forward-looking statements regarding the potential of the Company’s projects and interests and the development of the Company’s projects and interests and the development and therapeutic potential of the Company’s research and development projects. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company’s research and development projects will be successful or receive regulatory approvals or prove to be commercially successful in the future. Actual results of further R&D could differ from those projected or detailed in this report. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning the Company’s research and development program referred to in this Directors' report and in the Company’s ‘Operations Report’ as contained in this Annual report for the year ended 30 June 2017. Significant changes in state of affairs During 2017 Immuron Limited successfully listed with NASDAQ. There have been no other significant changes in the nature of Immuron Limited's principal activities during the financial year. Event since the end of the financial year 28 July 2017 - The Company issued 399,045 fully paid ordinary shares for repayment of $75,333.35 Convertible Note Security in accordance with executed funding agreement with a New York based investment funds provider announced to the ASX on 17 February 2017. 3 August 2017 - The Company announced to the ASX the resignation of Mr Thomas Liquard and the appointment of Dr Jerry Kanellos as the interim CEO. Immuron’s Chief Operating and Scientific Officer Dr Jerry Kanellos assumed the role of Interim-Chief Executive Officer from 1 August 2017. For Dr Kanellos’ increased role at Immuron his total remuneration package has increased to $230,000 per annum. Dr Kanellos’ contract has a 30-day termination notice period. Other than the events listed above, there have not been any other matters or circumstances in the financial statements or notes thereto, that have arisen since the end of the financial year which significantly affected, or may significantly affect, the operations of Immuron Limited the results of those operations or the state of affairs of Immuron Limited in future financial years. 11 Immuron Limited Directors' report 30 June 2017 (continued) Business strategy, future developments and prospects Immuron aims to create value for shareholders through a two-pronged approach. In the short and medium term Immuron sells and licenses Travelan, an over-the-counter product. Beyond the short Immuron is researching and developing prescription products, principally for the treatment of NASH and Clostridium difficile. term, The Company continues to develop its NASH, ASH and C-Diff products. These development programs are not expected to generate revenues in the short term however, in the longer term, and pending a successful development outcome in particular the NASH and ASH clinical trials, each of these development programs could increase shareholder value by many multiples. Environmental regulation The Company is involved in pharmaceutical research and development. Much of which is contracted out to third parties, and it these activities do not create any significant/material environmental impact. To the best of the Company's knowledge, the scientific research activities undertaken by, or on behalf of, the Company are in full compliance with all prescribed environmental regulations. is the Directors understanding that 12 Immuron Limited Directors' report 30 June 2017 (continued) Information on directors Dr Roger Aston Independent Non-Executive Chairman Appointed to the Board 20 March 2012 Last elected by shareholders Experience and expertise 13 November 2014 Dr. Aston has more than 20 years of experience in the pharmaceutical and biotech industries. Dr. Aston was previously the Chief Executive Officer and a Director of Mayne Pharma Group Limited. Prior to his position at Mayne Pharma, some of his previous positions have included CEO of Peptech Limited (Australia), Director of Cambridge Antibody Technology Limited (UK), and Chairman of Bio Focus Plc (formally: Cambridge Drug Discovery Limited). Dr. Aston was also founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr. Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr. Aston has been closely involved in the development of many successful pharmaceutical and biotechnology companies. Dr. Aston has extensive experience including negotiating global licence agreements, overseeing product the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. registration activities with the FDA, Qualifications BSc (Hons), PhD Directorships held in other public entities Dr. Aston is currently a director of: - Pharmaust Limited (ASX:PAA) - Current Executive Chairman (12 Aug 2013) - Oncosil Limited (ASX:OSL) - Non-Executive Chairman (stepped down 8 May 2017) - Oncosil Limited (ASX:OSL) - Current Non-Executive Chairman (28 Mar 2013) - Regeneus Limited (ASX:RGS) - Current Non-Executive Chairman (21 Sep 2012) - Resapp Health Limited (ASX:RAP) - Current Chairman (2 Jul 2015) Other listed directorships held during the past 3 years Dr. Aston has been a Director of the following entities in the past 3 years: - PolyNovo Limited (ASX:PBV) (Formally: Calzada Limited (ASX:CZD)) - 15 November 2013 to 10 September 2014 - IDT Limited (ASX:IDT) - 20 March 2012 to 20 November 2013 Committees Chairman and Member of the Company’s Remuneration Committee; and Member of the Company’s Audit and Risk Committee. Interests in shares and options Shares Options 751,116 fully paid ordinary shares 3,282,950 options 13 Immuron Limited Directors' report 30 June 2017 (continued) Information on directors (continued) Mr Daniel Pollock Independent Non-Executive Director Appointed to the Board 11 October 2012 Last elected by shareholders Experience and expertise 25 November 2015 Mr. Pollock is a lawyer admitted in both Scotland and Australia and holding Practicing Certificates in both Jurisdictions. He is a sole practitioner in his own legal firm based in Melbourne, Australia which operates internationally and specializes in commercial law. Mr. Pollock is Chairman of Amaero Pty Ltd, a company established to commercialise laser based additive manufacturing emerging from Monash University. He is also Executive Director and co-owner of Great Accommodation P/L a property management business operating in Victoria. Mr. Pollock has had historical involvement as a seed investor and Board member of a number of small unlisted companies. The most recent of these was an e-Pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company. Qualifications LL.B; Dip L.P Directorships held in other public entities Other listed directorships held during the past 3 years Nil Nil Committees Chairman and Member of the Company’s Audit and Risk Committee; and Member of the Company’s Remuneration Committee. Interests in shares and options Shares Options 374,800 fully paid ordinary shares 1,134,800 options 14 Immuron Limited Directors' report 30 June 2017 (continued) Information on directors (continued) Mr Stephen Anastasiou Non-Executive Director Appointed to the Board 28 May 2013 Last elected by shareholders Experience and expertise 29 November 2016 Mr. Anastasiou has over 20 years’ experience in general management, marketing and strategic planning within the healthcare industry. His breadth of experience incorporates medical diagnostics, pharmaceuticals, hospital, dental and OTC products, with companies including the international pharmaceutical company Bristol Myer Squibb. While working with KPMG Peat Marwick as a management consultant, Mr. Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management. Mr. Anastasiou’s companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies. Qualifications BSc (Hons), Grad. Dip MKTG, MBA Directorships held in other public entities Other listed directorships held during the past 3 years Committees Nil Nil Nil Interests in shares and options Shares Options 5,376,137 fully paid ordinary shares 3,247,017 options 15 Immuron Limited Directors' report 30 June 2017 (continued) Information on directors (continued) Mr Peter Anastasiou Executive Vice Chairman Appointed to the Board 21 May 2015 Last elected by shareholders Experience and expertise 25 November 2015 Mr. Anastasiou is a serial entrepreneur and investor with extensive experience in business both in Australia and overseas. Over the past 25 years, he has been credited with rebuilding a number of companies through the implementation of various corporate restructurings, acquisitions and solid financial management practices, with his most recent success being managing the restructuring of SABCO to ensure the future of this 100 year old iconic Australian company. Mr. Anastasiou’s involvement with Immuron commenced in May 2013 following his substantial underwriting support of the Company’s Renounceable Rights Issue, which was surpassed by his further funding support of the $9.66M (before costs) capital raising in February 2014 resulting in an ownership of approx. 15% of the Company via his associated investment funds. Mr. Anastasiou was the founding Chairman of the ACSI Group of Companies, which has owned and managed successful consumer companies such as SABCO, Britex Carpet care, Rug Doctor and Crystal Clear. Mr. Anastasiou also has a number of philanthropic interests including being a patron of the Identity Theatre for men, a prior board member and supporter of the Indigenous Eye Health Unit at Melbourne University, a supporter of the John Fawcett Foundation in Bali, and a founding investor and Director of Melbourne Victory Football Club. Qualifications B.Psych Directorships held in other public entities Other listed directorships held during the past 3 years Committees Nil Nil Nil Interests in shares and options Shares Options 15,327,746 fully paid ordinary shares 5,158,409 options 16 Immuron Limited Directors' report 30 June 2017 (continued) Information on directors (continued) Prof Ravi Savarirayan Non-Executive Director Appointed to the Board 7 April 2017 Last elected by shareholders Experience and expertise N/A He is a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as Professor and Research Group Leader (Skeletal Biology and Disease) at the Murdoch Children’s Research Institute since September 2000. Mr. Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium since January 2011 and has been the Chair of the Specialist Advisory Committee in Clinical Genetics, Royal Australasian College of Physicians since February 2009 . He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several International Working Committees on Constitutional Diseases of Bone. Mr. Savarirayan’s primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 150 peer-reviewed articles, collaborating with peers from over 30 countries, and has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics since July 2007, American Journal of Medical Genetics since December 2011 and Journal of Medical Genetics since June 2005. Mr. Savarirayan received his MBBS from the University of Adelaide in 1990 and became a fellow of the Royal Australasian College of Physicians in December 1997. He was certified as a specialist in clinical genetics from the Human Genetics Society of Australasia in 1998 and received his Doctor of Medicine from the University of Melbourne in 2004, for his thesis “Clinical and Molecular Studies in the Osteochondrodysplasias.” Qualifications MD (Melb.), BS, FRACP, ARCPA (Hon.) Directorships held in other public entities Other listed directorships held during the past 3 years Committees Nil Nil Nil Interests in shares and options Shares Options Nil fully paid ordinary shares 1,000,000 options* *On 22 June 201, the Company issued Professor Ravi Savarirayan, 1,000,000 unlisted options exercisable at $0.50 on or before 27 Nov 2019. These options are currently held in escrow and cannot be exercised until shareholder approval is granted. Company secretary Mr Phillip Hains Joint Company Secretary & Chief Financial Officer Mr. Hains was appointed as Company Secretary on 19 April 2013. Mr. Hains is a Chartered Accountant and specialist in the public company environment. He has served the needs of a number of public company boards of directors and related committees. He has over 20 years’ experience in providing accounting, administration, compliance and general management services. He holds a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants of Australia. 17 Immuron Limited Directors' report 30 June 2017 (continued) Company secretary (continued) Mr Peter Vaughan Joint Company Secretary & Chief Financial Officer Mr. Vaughan was appointed as Company Secretary on 19 April 2013. Mr. Vaughan is a Chartered Accountant who has worked in the listed company environment for more than 10 years across a number of industries. He has served on and provided accounting, administration, compliance and general management services to a number of private, not-for-profit and public company boards of directors and related committees. Chief Executive Officer Dr Jerry Kenellos Chief Executive Officer (CEO) and Chief Operating & Scientific Officer (COSO) Appointed as CEO 1 August 2017 Experience and expertise property intellectual development, project management, Dr. Jerry Kanellos has over twenty five years’ experience in the pharmaceutical and biotechnology industry, and has held leadership roles in executive management, portfolio business management research and development. From 2008 until 2012, Dr. Kanellos was the Chief Operating Officer of TransBio Limited where he was responsible for the strategic identification, development and maintenance of commercial partnerships globally, along with development, management and maintenance responsibility for the intellectual property portfolio, research and development and technology transfer. Prior to this, Dr. Kanellos work for five years as a consultant to the biotechnology industry and has provided development and commercialization strategies for various bodies including academic institutes, private and publicly listed companies and government departments both national and international. He has also been involved in the establishment and management of several startup biotechnology companies. During his ten years tenure in research and development at CSL Limited, a global specialty biotherapeutics company that develops and delivers innovative biotherapies, Dr. Kanellos gained considerable experience in the international drug development process, formulation development through to pharmaceutical scale up and cGMP manufacture successfully leading the Chemistry Manufacturing and Controls (CMC) programs for the approval, manufacture and launch of several products. Dr. Kanellos holds a PhD in Medicine from the University of Melbourne. Qualifications Directorships held in other public entities Other listed directorships held during the past 3 years Interests in shares and options PhD Nil Nil Shares Options Nil fully paid ordinary shares 200,000 options 18 Immuron Limited Directors' report 30 June 2017 (continued) Meetings of directors The numbers of meetings of the Company's board of Directors and of each board committee held during the year ended 30 June 2017, and the numbers of meetings attended by each Director were: Dr. Roger Aston Mr. Peter Anastasiou Mr. Daniel Pollock Mr. Stephen Anastasiou Prof. Ravi Savarirayan Meetings of directors Meetings of Committees Audit Remuneration A 12 12 12 12 2 B 12 12 12 12 2 A 3 - 3 - - B 3 - 3 - - A - - - - - B - - - - - A = Number of meetings attended B = Number of meetings held during the time the Director held office or was a member of the committee during the year As at the date of this report the Company had an Audit and Risk Committee and Remuneration Committee with membership of the committees as follows: Chairman Members Audit and Risk Committee Mr. Daniel Pollock Dr. Roger Aston Remuneration Committee Dr. Roger Aston Mr. Daniel Pollock Indemnification and Insurance of Directors and other Officers Under the Company's constitution: (a) To the extent permitted by law and subject to the restrictions in section 199A and 199B of the Corporations Act 2001, the Company indemnifies every person who is or has been an officer of the Company against any liability (other than for legal costs) incurred by that person as an officer of the Company where the Company requested the officer to accept appointment as Director. (b) To the extent permitted by law and subject to the restrictions in sections 199A and 199B of the Corporations Act 2001, the Company indemnifies every person who is or has been an officer of the Company against reasonable legal costs incurred in defending an action for a liability incurred by that person as an officer of the Company. The Company has insured its Directors, the Company Secretaries and executive officers for the financial year ended 30 June 2017. Under the Company's Directors' and Officers' Liability Insurance Policy, the Company cannot release to any third party or otherwise publish details of the nature of the liabilities insured by the policy or the amount of the premium. Accordingly, the Company relies on section 300(9) of the Corporations Act 2001 to exempt it from the requirement to disclose the nature of the liability insured against and the premium amount of the relevant policy. The Company also has in place a Deed of Indemnity, Access and Insurance with each of the Directors. This Deed: (i) indemnifies the Director to the extent permitted by law and the Constitution against certain liabilities and legal costs incurred by the Director as an officer of the Company and subsidiary; (ii) requires the Company to maintain, and pay the premium for, a Directors and Officers Insurance Policy in respect of the Directors; and (iii) provides the Director with access to particular papers and documents requested by the Director for a Permitted Purpose; both during the time that the Director holds office and for a seven-year period after the Director ceases to be an officer of the Company and any subsidiary, on the terms and conditions contained in the Deed. 19 Immuron Limited Directors' report 30 June 2017 (continued) Indemnification and Insurance of Directors and other Officers (continued) Indemnification and Insurance of auditor The Company has not, during or since the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor. During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity. Shares Issued as a Result of the Exercise of Options No fully paid ordinary shares were issued from the exercise of options during the year ended 30 June 2017. Proceedings on Behalf of the Company No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings. No proceedings have been brought or intervened in on behalf of the Company with leave of the Court under section 237 of the Corporations Act 2001. Other Audit Services The Company’s Auditors, William Buck, did not provide any non-audit services during the 2017 financial year. During the year, the Company had engaged its US auditor Marcum LLP to assist with filing of the F-1 application form for listing on the NASDAQ exchange in the USA. Total fees charged for these services were AUD $470,503 (2016: $Nil). The directors are satisfied that the provision of these services is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The nature and scope of the audit services provided means that auditor independence was not compromised. Auditor’s Independence Declaration The Auditors Independence Declaration as required under section 307C of the Corporations Act 2001 for the year ended 30 June 2017 has been received and can be found in the ‘Auditor’s Independence Declaration’ section of this Annual Report. Corporate Governance In recognising the need for the highest standards of corporate behaviour and accountability, the Directors of Immuron support and adhere to good corporate governance practices. The Company's Corporate Governance Statement is available on the Company’s website together with the Board Skills Matrix at www.immuron.com. Remuneration report This Remuneration Report outlines the Director and Executive remuneration arrangements of the Company as required by the Corporations Act 2001 and its Regulations. This report details the nature and amount of remuneration of each Director of Immuron Limited and all other Key Management Personnel. For the purposes of this report, Key Management Personnel (KMP) are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any Director (whether Executive or otherwise) of the Company. For the purposes of this report, the term 'executive' encompasses the chief executive, senior executives, and secretaries of the Company. This report details the nature and amount of remuneration for each Director of Immuron Limited, and for the other Key Management Personnel. 20 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) The Directors of Immuron Limited during the year were: Dr. Roger Aston Independent non-executive chairman Mr. Peter Anastasiou Executive vice chairman Mr. Daniel Pollock Independent non-executive director Mr. Stephen Anastasiou Independent non-executive director Prof. Ravi Savarirayan Independent non-executive director (appointed 7 April 2017) The following persons held office as Key Management Personnel of Immuron Limited during the financial year with the following changes subsequent to 30 June 2017: Dr. Jerry Kenellos Interim Chief Executive Officer (CEO), (appointed 3 August 2017) and Chief Operating & Scientific Officer (COSO) Mr. Thomas Liquard Chief Executive Officer (CEO) (resigned 3 August 2017) (a) Section A: Principles used to determine the nature and amount of Remuneration Remuneration Policy The Remuneration Policy ensures that Directors and Senior Management are appropriately remunerated having industry regard to their norms/standards and the general pay environment as appropriate. The Remuneration Policy has been established to enable the Company to attract, motivate and retain suitably qualified Directors and Senior Management who will create value for shareholders. relevant experience, the performance of their performance, the Company, Remuneration Policy versus Company Performance The Company's Remuneration Policy is not directly based on the Company's earnings. The Company's earnings have remained negative since inception due to the nature of the Company. Shareholder wealth reflects this speculative and volatile market sector. No dividends have ever been declared by the Company. The Company continues to focus on the research and development of its intellectual property portfolio with the objective of achieving key development and commercial milestones in order to add further Shareholder value. The Company’s performance over the previous five financial years is as follows: Financial year Net loss ($) Share price at year end 2017 2016 2015 2014 2013 6,804,154 5,599,004 3,447,951 2,544,550 3,539,117 $0.27 $0.25 $0.23* $0.20* $0.16* * Share prices have been adjusted to reflect a 40:1 capital consolidation which was completed on 20 Nov 2014 Remuneration Committee The Remuneration Committee of the Board of Directors of Immuron Limited is responsible for overseeing the Remuneration Policy of the Company and for recommending or making such changes to the policy as it deems appropriate. Non-Executive Director Remuneration Objective The Remuneration Policy ensures that Non-Executive Directors are appropriately remunerated having regard to their relevant experience, individual performance, the performance of the Company, industry norms/standards and the general pay environment as appropriate. 21 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (a) Section A: Principles used to determine the nature and amount of Remuneration (continued) Non-Executive Director Remuneration (continued) Structure The Company's Constitution and the ASX Listing Rules specify that the aggregate remuneration of Non-Executive Directors shall be determined from time to time by a Meeting of Shareholders. An amount (not exceeding the amount approved at the Shareholders Meeting) is determined by the Board and then divided between the Non-Executive Directors as agreed. The latest determination was at the Shareholders Meeting held on 8 November 2005 when shareholders approved the aggregate maximum sum to be paid or provided as remuneration to Non-Executive Directors as a whole (other than the Managing Director, CEO and Executive Directors) for their services as $350,000 per annum. In the year ended 30 June 2017, the Non-Executive Directors and Executive Directors were remunerated an aggregate $444,373 and $69,050, respectively per annum, including superannuation and any equity issued during the period. Equity issued to directors were approved by shareholders as consideration for additional services provided to the Company. The manner in which the aggregate remuneration is apportioned amongst Non-Executive Directors is reviewed periodically. The Board is responsible for reviewing its own performance. Board, and Board committee performance, is monitored on an informal basis throughout the year with a formal review conducted during the financial year. No retirement benefits are payable other than statutory superannuation, if applicable. Executive Director and Executive Officer Remuneration Objective The Remuneration Policy ensures that Executive Directors are appropriately remunerated having regard to their relevant experience, individual performance, the performance of the Company, industry norms/standards and the general pay environment as appropriate. Structure The Non-Executive Directors are responsible for evaluating the performance of the Chief Executive Officer (CEO) who in turn evaluates the performance of the other Senior Executives. The evaluation process is intended to assess the Company's business performance, whether long-term strategic objectives are being achieved and the achievement of individual performance objectives. The performance of the CEO and Senior Executives are monitored on an informal basis throughout the year and a formal evaluation is performed annually. Fixed Remuneration Executives' fixed remuneration comprises salary and superannuation and is reviewed annually by the CEO, and in turn, the Remuneration Committee. This review takes into account the Executives' experience, performance in achieving agreed objectives and market factors as appropriate. Variable Remuneration – Short Term Incentive Scheme All Executives are entitled to participate in the Employee Short Term Incentive Scheme which provides for executive employees to receive a combination of short term incentive (STI) as part of their total remuneration if they achieve certain performance indicators as set by the Board. The STI can be paid either by cash, or a combination of cash and the issue of equity in the Company, at the determination of the Board and Remuneration Committee. 22 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (a) Section A: Principles used to determine the nature and amount of Remuneration (continued) Executive Director and Executive Officer Remuneration (continued) Variable Remuneration – Long Term Incentive Scheme Executives may also be provided with longer-term incentives through the Company's Executive Share Option Plan (ESOP), that was approved by shareholders at the Annual General Meeting held on 13 November 2014. The aim of the ESOP is to allow the Executives to participate in, and benefit from, the growth of the Company as a result of their efforts and to assist in motivating and retaining those key employees over the long term. Continued service is the condition attached to the vesting of the options. The Board at its discretion determines the total number of options granted to each Executive. Voting and Comments Made at the Company’s 2016 Annual General Meeting The Company received 99.76% of the “YES” votes on the resolution pertaining to shareholders voting on the remuneration report for the 2016 financial year. There were no specific comments raised at the Annual General Meeting or throughout the year on its remuneration practices. (b) Section B: Details of remuneration Details of remuneration for the year ended 30 June 2017 The remuneration for each Director and each of the other Key Management Personnel of the Company during the year ended 30 June 2017 was as follows: 2017 Short-term employee benefits Post- employment benefits Share based payments Cash salary and fees $ Cash bonus $ Non- monetary benefits $ Super- annuation $ Shares/ Options $ Total $ Directors Dr. Roger Aston Mr. Daniel Pollock Mr. Stephen Anastasiou Mr. Peter Anastasiou Prof. Ravi Savarirayan Total Other key management personnel Dr. Jerry Kenellos Mr. Thomas Liquard Total Total 64,375 48,750 42,500 42,500 12,501 210,626 160,000 311,040 471,040 681,666 - - - - - - - - - - - - - - - - - - - - 6,116 4,631 - - - 10,747 212,400 26,550 26,550 26,550 - 292,050 282,891 79,931 69,050 69,050 12,501 513,423 15,200 - 15,200 28,620 33,000 203,820 344,040 61,620 547,860 25,947 353,670 1,061,283 Details of remuneration for the year ended 30 June 2016 The remuneration for each Director and each of the other Key Management Personnel of the Company during the year ended 30 June 2016 was as follows: 23 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (b) Section B: Details of remuneration (continued) Details of remuneration for the year ended 30 June 2016 (continued) 2016 Short-term employee benefits Post- employment benefits Share based payments Cash salary and fees $ Cash bonus $ Non- monetary benefits $ Super- annuation $ Shares/ Options* $ Total $ Directors Dr. Roger Aston Mr. Daniel Pollock Mr. Stephen Anastasiou Mr. Peter Anastasiou Total Other key management personnel Dr. Jerry Kenellos Mr. Thomas Liquard Dr. Leearne Hinch Total Total 62,500 45,000 40,000 40,000 187,500 149,744 287,485 27,785 465,014 652,514 - - - - - - - - - - - - - - - - - - - - 5,938 4,275 - - 730,125 292,050 292,050 292,050 798,563 341,325 332,050 332,050 10,213 1,606,275 1,803,988 14,226 - 1,565 15,791 - - - - 163,970 287,485 29,350 480,805 26,004 1,606,275 2,284,793 An adjustment of AUD$1,209,338 was made to the Total reserves balance at 30 June 2016 as compared to the previous statement lodged with ASX, as a result of a change in volatility assessment. Effectively, this resulted in an increase in Consulting, Employee and Director expense and the Loss for the period on the Statement of Profit or Loss and Other Comprehensive income. Refer to note 9(b) for more details. Fully paid ordinary shares held The number of shares in the Company held during the financial year by each Director and other Key Management Personnel of the Company, including their personally related parties, are set out below. 2017 Directors Dr. Roger Aston Mr. Daniel Pollock Mr. Stephen Anastasiou Mr. Peter Anastasiou Prof. Ravi Ssavarirayan Total Other key management personnel Mr. Jerry Kenellos Mr. Thomas Liquard Total Opening balance No. Granted as compensation No. Net change - other No. Closing balance No. 607,116 319,640 4,067,857 13,663,364 - 18,657,977 - - - - - - 144,000 (19,640) 1,308,280 1,308,280 - 2,740,920 751,116 300,000 5,376,137 14,971,644 - 21,398,897 - - - - 134,694 134,694 - - - - 134,694 134,694 Total 18,657,977 134,694 2,740,920 21,533,591 24 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (b) Section B: Details of remuneration (continued) Fully paid ordinary shares held (continued) Net Change - Other No: Securities acquired or disposed of on market during the period, including securities acquired via the Rights Issue from the NASDAQ Listing as announced to the market on 9 June 2017. No shares were granted to Directors or Key Management in relation to remuneration during the 2017 financial year. Post 30 June 2017, the following directors had movement in their shareholding: • Mr Daniel Pollock acquired 74,800 shares on 6 September 2017. Mr Pollock currently holds 374,800 fully paid ordinary shares in Immuron Limited. • Mr Peter Anastasiou acquired 355,802 shares on various different acquisition dates. Mr P Anastasious currently holds 15,327,746 fully paid ordinary shares in Immuron Limited. 2016 Directors Dr. Roger Aston Mr. Daniel Pollock Mr. Stephen Anastasiou Mr. Peter Anastasiou Total Other key management personnel Mr. Jerry Kenellos Mr. Thomas Liquard Dr. Leearne Hinch Total Opening balance $ Granted as compensation $ Net change - other $ Closing balance $ 468,166 304,640 2,035,371 10,022,360 (12,830,537) - - - - - - - - - - - - - - 138,950 15,000 2,032,486 3,641,004 (5,827,440) 607,116 319,640 4,067,857 13,663,364 (18,657,977) - - - - - - - - 5,827,440 18,657,977 Total 12,830,537 Net Change - Other No: Securities acquired or disposed of on market during the period, including securities acquired via the Rights Issue as announced to the market on 5 July 2016. No shares were granted to Directors or Key Management in relation to remuneration during the 2016 financial year. Shares and options may be granted to key management personnel under the various share based compensation plans as set out in section C of this report. Details of shares and options provided as part of the total remuneration paid to key management personnel are set out below. When exercisable, each option is convertible into one ordinary fully paid share of Immuron Limited. Options and rights held The number of options over ordinary shares in the Company held during the financial year by each Director of Immuron Limited and other Key Management Personnel of the Company, including their personally related parties, are set out below: 25 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (b) Section B: Details of remuneration (continued) Options and rights held (continued) 2017 Directors Dr. Roger Aston* Mr. Daniel Pollock* Mr. Stephen Anastasiou* Mr. Peter Anastasiou* Prof. Ravi Savarirayan** Total key management Other personnel Mr. Thomas Liquard Mr. Jerry Kenellos*** Total Opening balance No. Options expired or lapsed No. Net change - other No. Closing balance No. Vested and exercisable No. Unvested No. 3,500,000 1,250,000 1,250,000 1,000,000 - 7,000,000 (500,000) (250,000) (250,000) - - (1,000,000) 282,950 60,000 2,247,017 3,726,409 1,000,000 7,316,376 3,282,950 1,060,000 3,247,017 4,726,409 1,000,000 13,316,376 3,282,950 1,060,000 3,247,017 4,726,409 - 12,316,376 - - - - 1,000,000 1,000,000 - - - - - - - 200,000 200,000 - 200,000 200,000 - - - - - - Total 7,000,000 (1,000,000) 7,516,376 13,516,376 12,316,376 1,000,000 *Net Change - Other No: Securities acquired or disposed of on market during the period, including securities acquired via the Rights Issue from the NASDAQ Listing as announced to the market on 9 June 2017. **On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 27 Nov 2019. These options are currently held in escrow and cannot be exercised until shareholder approval is granted. ***Issue of Unlisted Options in lieu of cash payment under Immuron Limited ESOP. Post 30 June 2017, the following directors had movement in their shareholding: • Mr Daniel Pollock acquired 74,800 options on 6 September 2017. Mr Pollock currently holds 1,134,800 options in Immuron Limited. • Mr Peter Anastasiou acquired 432,000 options on 18 August 2017. Mr P Anastasious currently holds 5,158,409 options in Immuron Limited. 26 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (b) Section B: Details of remuneration (continued) Options and rights held (continued) 2016 Directors Dr. Roger Aston* Mr. Daniel Pollock* Mr. Stephen Anastasiou* Mr. Peter Anastasiou** Total key management Other personnel Mr. Thomas Liquard Mr. Jerry Kenellos Dr. Leearne Hinch Total Opening balance No. Options expired or lapsed No. Net change - other No. Closing balance No. Vested and exercisable No. Unvested No. 604,166 291,666 250,000 1,666,666 2,812,498 (104,166) (41,666) - (1,110,666) (1,256,498) 3,000,000 1,000,000 1,000,000 444,000 5,444,000 3,500,000 1,250,000 1,250,000 1,000,000 7,000,000 500,000 250,000 250,000 - 1,000,000 3,000,000 1,000,000 1,000,000 1,000,000 6,000,000 - - - - - - - - - - - - - - - - - - - - - - - - Total 2,812,498 (1,256,498) 5,444,000 7,000,000 1,000,000 6,000,000 *Issue of Unlisted Options in lieu of cash payment for additional services as per Resolution 5A - 5D of the AGM held on 25 Nov 2015. **Issue of Unlisted Options in lieu of cash payment for additional services as per Resolution 5A - 5D of the AGM held on 25 Nov 2015. Mr Peter Anastasiou also exercised 556,000 IMCAI Unlisted Options into Ordinary Shares at exercise price of $0.376. Additional information in respect of options The terms and conditions of each grant of options over ordinary fully paid shares affecting remuneration of directors and key management personnel in this financial year or future reporting years are as follows: Number of options 5,000,000 1,000,000 200,000 Grant date a 27-Nov-15 27-Nov-15 09-Dec-16 Vesting date and exercisable date Expiry date Exercise price $ Fair value at grant date $ 06-Aug-16 06-Aug-17 09-Dec-16 27-Nov-19 27-Nov-19 27-Nov-19 0.500 0.500 0.500 0.082 0.082 0.143 The above quantities and values have been adjusted to reflect a 40:1 capital consolidation which was completed on 20 Nov 2014. On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 27 Nov 2019. These options are currently held in escrow and cannot be exercised until shareholder approval is granted. Options granted carry no dividend or voting rights and the value of the grant was determined in accordance with applicable Australian Accounting Standards. The number of options over ordinary shares granted to and vested by directors and key management personnel as part of compensation is set out below: 27 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (b) Section B: Details of remuneration (continued) Additional information in respect of options (continued) Directors: Dr. Roger Aston Mr. Daniel Pollock Mr. Stephen Anastasiou Mr. Peter Anastasiou Prof. Ravi Savarirayan* Total a Other key management personnel: Mr. Jerry Kenellos Mr. Thomas Liquard Total a Total Total value of options granted during the year $ 2017 2016 Value of options exercised during the year $ 2017 2016 Value of options lapsed during the year $ 2017 2016 212,400 730,125 26,550 292,050 26,550 292,050 26,550 292,050 - - 292,050 1,606,275 28,620 - 28,620 - - - 320,670 1,606,275 - - - - - - - - - - - - - 35,806 - 35,806 8,762 50,800 3,505 25,400 - 25,400 93,426 - - - 101,600 105,693 - - - - - - - - - 35,806 101,600 105,693 *On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 27 Nov 2019. These options are currently held in escrow and cannot be exercised until shareholder approval is granted. The relative proportions of remuneration that are linked to performance and those that are fixed are as follows: Directors: Dr. Roger Aston Mr. Daniel Pollock Mr. Stephen Anastasiou Mr. Peter Anastasiou Prof. Ravi Savarirayan a Other key management personnel: Mr. Jerry Kenellos Mr. Thomas Liquard Fixed remuneration 2017 2016 At risk - STI 2017 2016 At risk - LTI 2017 2016 25% 67% 62% 62% 100% 61% 33% 45% 45% - 86% 90% 100% 100% 75% 33% 38% 38% - 14% 10% 39% 67% 55% 55% - - - - - - - - - - - - - - - - - Loans to/from Directors and Other Key Management Personnel The Company received a short term Loan from Grandlodge Capital Pty Ltd, part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. The short-term funding is a cash advance against the anticipated refund Immuron will receive from the Australian Taxation Office under the Research and Development Income Tax Concession Incentive for the Company's eligible R&D expenditure incurred for financial year of 2016 and 2017. Other transactions with Directors or Other Key Management Personnel Services rendered by Grandlodge Pty Ltd to Immuron Ltd: Grandlodge, and its associated entities, are marketing, warehousing and distribution logistics companies. Mr David Plush is also an owner of Grandlodge, and its associated entities. 28 Immuron Limited Directors' report 30 June 2017 (continued) Remuneration report (continued) (b) Section B: Details of remuneration (continued) Other transactions with Directors or Other Key Management Personnel (continued) Services rendered by Grandlodge Pty Ltd to Immuron Ltd: (continued) Commencing on 1st June 2013, Grandlodge was verbally contracted to provide warehousing, distribution and invoicing services for Immuron’s products for AUD$70,000 per annum. These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price of AUD$0.16 per share representing Immuron Limited’s share price at the commencement of the verbal agreement. The shares to be issued to Grandlodge, or its associated entities, as compensation in lieu of cash payment for the services rendered under this verbal agreement have been subject to the approval of Immuron shareholders at Company shareholder meetings held over the past 18 months. Grandlodge will also be reimbursed in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the verbal agreement, unless both parties agree to an alternative method of payment. Premises Rental services received from Wattle Laboratories Pty Ltd to Immuron Ltd: Wattle Laboratories Pty Ltd (Wattle) is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Commencing on 1 January 2016, Immuron executed a 3 year Lease Agreement with Wattle whereby Immuron will lease part of their Blackburn office facilities for Immuron's operations at an arms-length commercial rental rate of $38,940 per annum, payable in monthly installments. Section C: Employment Contracts of Key Management Personnel As at 30 June 2017, the following contracts are in place for Directors or Key Management Personnel: Title Dr. Jerry Kenellos Nature of change Notice Requirements Until by either party. termination For any reason Dr Kanellos may terminate the agreement by providing 30 days' notice. Termination Requirements Pay Dr Kenellos on termination any unpaid salary, reimburse all business expenses submitted with appropriate documentation. Section D: Additional Information No loans have been made to any Director, any member of the Key Management Personnel, or any of their related entities, or any executive during the 2017 financial year (2016: $Nil). This completed the Remuneration Report of Immuron Limited for 30 June 2017 Immuron Limited Corporate Governance Statement for financial year ended 30 June 2017 can be found on Immuron Limited website: www.immuron.com This report is made in accordance with a resolution of Directors. Dr. Roger Aston Director Melbourne 28 September 2017 29 Immuron Limited Consolidated statement of profit or loss and other comprehensive income For the year ended 30 June 2017 Revenue Sale of goods Total operating revenue Cost of goods sold Gross profit Direct Selling Costs Sales and marketing costs Freight costs Total gross profit less direct selling costs Other income Expenses Consulting, employee and director Corporate administration Depreciation Finance fee costs Impairment of inventory Marketing and promotion Research and development Travel and entertainment expenses Loss before income tax Income tax expense Loss for the period Consolidated entity 2017 $ Restated 2016 $ Notes 2 2 3 3 4 1,396,197 1,396,197 1,001,077 1,001,077 (337,546) 1,058,651 (301,435) 699,642 (407,751) (135,377) 515,523 (133,781) (134,967) 430,894 1,614,373 3,008,778 (1,689,521) (1,381,809) (4,922) (24,483) (136,494) (789,608) (4,630,674) (276,539) (6,804,154) (2,840,037) (1,320,570) (3,892) (341,600) (4,176) (487,591) (3,623,961) (416,849) (5,599,004) - (6,804,154) - (5,599,004) Other comprehensive income for the period, net of tax 40,017 8,846 Total comprehensive loss for the period (6,764,137) (5,590,158) Cents Cents Earnings per share for profit attributable to the ordinary equity holders of the Company: Basic/diluted loss per share (cents) 18 (6.4) (7.3) The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes. 31 Immuron Limited Consolidated statement of financial position As at 30 June 2017 Notes 5(b) 5(a) 6(a) 6(b) Consolidated entity 2017 $ Restated 2016 $ 3,994,924 1,768,237 2,336,127 168,366 8,267,654 2,290,639 4,387,772 2,056,067 74,943 8,809,421 18,837 18,837 18,063 18,063 8,286,491 8,827,484 5(c) 5(d) 5(d) 6(c) 1,326,562 139,864 226,000 19,139 1,711,565 1,986,407 772,397 1,128,117 - 3,886,921 1,711,565 3,886,921 6,574,926 4,940,563 7(a) 7(b) 53,632,995 2,470,417 (49,528,486) 45,633,354 2,128,566 (42,821,357) 6,574,926 4,940,563 ASSETS Current assets Cash and cash equivalents Trade and other receivables Inventories Other current assets Total current assets Non-current assets Plant and equipment Total non-current assets Total assets LIABILITIES Current liabilities Trade and other payables Borrowings Other financial liabilities Deferred revenue Total current liabilities Total liabilities Net assets EQUITY Issued capital Reserves Accumulated losses Total equity The above consolidated statement of financial position should be read in conjunction with the accompanying notes. 32 Immuron Limited Consolidated statement of changes in equity For the year ended 30 June 2017 Attributable to owners of Immuron Limited Consolidated entity Notes Issued capital $ Reserves $ Accumulated losses $ Total $ Balance at 1 July 2015 40,335,347 548,065 (37,542,573) 3,340,839 Loss for the period Other comprehensive income Total comprehensive (loss) income for the period Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs Treasury shares Shares to be issued Options issued/expensed Lapse or exercise of share options 7(a) 7(a) 7(b) 7(b) - - - - 8,846 8,846 (5,599,004) - (5,599,004) 8,846 (5,599,004) (5,590,158) 1,586,629 (800,000) 4,511,378 - - 5,298,007 - - - 1,891,875 (320,220) 1,571,655 - - - - 320,220 320,220 1,586,629 (800,000) 4,511,378 1,891,875 - 7,189,882 Balance at 30 June 2016 (Restated) 45,633,354 2,128,566 (42,821,357) 4,940,563 Balance at 1 July 2016 (Restated) 45,633,354 2,128,566 (42,821,357) 4,940,563 Loss for the period Other comprehensive income Total comprehensive (loss) income for the period Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs Options and warrants issued/expensed Lapse or exercise of share options 7(a) 7(b) 7(b) - - - - 40,017 40,017 (6,804,154) - (6,804,154) 40,017 (6,804,154) (6,764,137) 7,927,766 - 71,875 7,999,641 - - 7,927,766 470,734 (168,900) 301,834 - 97,025 97,025 470,734 - 8,398,500 Balance at 30 June 2017 53,632,995 2,470,417 (49,528,486) 6,574,926 The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes. 33 Immuron Limited Consolidated statement of cash flows For the year ended 30 June 2017 Consolidated entity 2017 $ Restated 2016 $ Notes Cash flows from operating activities Receipts from customers Payments to suppliers and employees Interest received Other - R&D tax concession refund and other government grants Interest and other costs of finance paid Net cash used in operating activities 1,413,676 (9,971,142) 8,386 1,615,043 (97,051) (7,031,088) 1,114,596 (7,710,997) 12,165 1,469,763 (43,863) (5,158,336) 8(a) Cash flows from investing activities Payments for property, plant and equipment Net cash used from investing activities Cash flows from financing activities Proceeds from issues of shares and other equity securities Proceeds from borrowings Repayment of borrowings Capital raising cost Net cash provided from financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at the beginning of the financial year Effects of exchange rate changes on cash and cash equivalents Cash and cash equivalents at end of period 5(b) (5,696) (5,696) (2,441) (2,441) 12,525,067 500,000 (2,191,593) (2,132,422) 8,701,052 1,664,268 2,290,639 40,017 3,994,924 2,482,861 2,950,000 (1,077,220) (20,299) 4,335,342 (825,435) 3,116,074 - 2,290,639 The above consolidated statement of cash flows should be read in conjunction with the accompanying notes. 34 Immuron Limited Notes to the consolidated financial statements 30 June 2017 1 Segment information (a) Description of segments and principal activities The entity has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources. The executive management team considers the business from both a product and a geographic perspective and has identified three reportable segments. Research and Development (R&D): Income and expenses directly attributable to the Company’s research and development projects performed in Australia, Israel and United States. HyperImmune Products: Income and expenses directly attributable to Travelan activities which occur in Australia, New Zealand, US and Canada. In 2017, the Company earned 64%, 10% and 26% of its revenues from customers located in Australia, Canada and US, respectively. In 2016, the Company earned 78%, 4% and 18% of its revenues from customers located in Australia, Canada and US, respectively. Corporate: Other items of income and expenses not directly attributable to R&D or HyperImmune Products segment are disclosed as corporate costs. Corporate activities primarily occur within Australia. This segment includes interest expenses from financing activities and depreciation. (b) Segment results Consolidated entity 2017 Research & Development HyperImmune Products Corporate Total $ $ $ $ Segment revenue & other income Revenue from external customers R&D tax concession refund Interest income Other income Total Segment revenue & other income - 1,575,315 - 25,000 1,396,197 - - 5,672 1,600,315 1,401,869 - - 8,386 - 8,386 1,396,197 1,575,315 8,386 30,672 3,010,570 Segment expenses Depreciation Finance fee costs Share-based payments Other operating expenses Total segment expenses Income tax expense (Loss)/profit for the year Assets Segment assets Total assets Liabilities Segment liabilities Total liabilities - - (188,481) (4,805,874) (4,994,355) - (3,394,040) - - - (1,017,169) (1,017,169) (4,922) (24,483) (334,184) (3,439,611) (3,803,200) (4,922) (24,483) (522,665) (9,262,654) (9,814,724) - 384,700 - (3,794,814) - (6,804,154) 1,498,112 1,498,112 2,585,755 2,585,755 4,202,624 4,202,624 8,286,491 8,286,491 (514,326) (514,326) (330,218) (330,218) (867,021) (867,021) (1,711,565) (1,711,565) (3,098,427) (3,987,624) (4,211,010) (11,297,061) 35 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 1 Segment information (continued) (b) Segment results (continued) Consolidated entity 2016 Restated Segment revenue & other income Revenue from external customers R&D tax concession refund Interest income Other income Total Segment revenue & other income Segment expenses Depreciation Finance fee costs Share-based payments Other operating expenses Total segment expenses Income tax expense (Loss)/profit for the year Assets Segment assets Total assets Liabilities Segment liabilities Total liabilities Research & Development HyperImmune Products Corporate Total $ $ $ $ - 2,982,603 - - 1,001,077 - - 10,200 - - 12,165 3,810 1,001,077 2,982,603 12,165 14,010 2,982,603 1,011,277 15,975 4,009,855 - - - (3,623,961) (3,623,961) - - - (570,183) (570,183) (3,892) (156,000) (2,079,375) (3,175,448) (5,414,715) (3,892) (156,000) (2,079,375) (7,369,592) (9,608,859) - (641,358) - 441,094 - (5,398,740) - (5,599,004) 1,512,840 1,512,840 2,318,860 2,318,860 4,995,784 4,995,784 8,827,484 8,827,484 (769,434) (769,434) (538,806) (538,806) (2,578,681) (2,578,681) (3,886,921) (3,886,921) Information on major customers: During the year ended 30 June 2017 and 2016, the Company had the following major customers (and their respective contribution to the Company's total revenue): (4,495,443) (3,330,137) (5,011,759) (12,837,339) Consolidated entity 2017 % 2016 % 13 34 15 15 10 - 16 43 22 - - - Customer A Customer B Customer C Customer D* Customer E Customer F* *Less than 10% of revenue for the respective year. No other single customers contributed 10% to the Company's revenue for the periods. 36 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) Consolidated entity 2017 $ 2016 $ 1,396,197 1,396,197 1,001,077 1,001,077 8,386 1,575,315 30,672 1,614,373 12,165 2,982,603 14,010 3,008,778 Consolidated entity 2017 $ Restated 2016 $ - 905,819 39,664 221,373 522,665 1,689,521 146,007 150,502 238,985 846,315 1,381,809 46,775 956,737 32,537 197,713 1,606,275 2,840,037 62,825 100,609 217,904 939,232 1,320,570 2 Revenue and other income Revenue from operating activities Sale of goods Total revenue from operating activities Other income Interest income R&D tax concession refund Other income Total other income 3 Expenses Consulting, employee and director Consulting expenses Wages and salaries expenses Superannuation and other employee related expenses Director expenses Share- based payments Total consulting, employee and director expenses Corporate administration Audit and accounting fees Insurances Foreign exchange (gain) / losses Corporate administration costs Total corporate administration expenses 4 Income tax expense (a) Numerical reconciliation of income tax expense to prima facie tax payable The Company has estimated total tax losses of $34,759,770 (2016: $27,955,616), representing a Deferred Tax Asset of $9,558,937 at 27.5% (2016: $8,386,685 at 30%) that has not been recognised in the Financial Statements. 37 5 Financial assets and financial liabilities (a) Trade and other receivables Trade receivables Subscription receivables Accrued income Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) Consolidated entity 2017 2016 Notes $ $ 270,125 154,217 - 2,612,139 5(a)(i) 5(a)(ii) 1,498,112 1,621,416 1,768,237 4,387,772 All trade and other receivables are non-interest bearings. For further detail please refer to Note 10. (i) Subscription receivables Represents uncleared funds from the capital raising as at 30 June 2016. Funds received 7 July 2016 upon the issuance of shares. (ii) Accrued income Primarily comprises of receivables from the Australian Tax Office in relation to R&D tax concession for the year. (b) Cash and cash equivalents Current assets Cash at bank and in hand Consolidated entity 2017 $ 2016 $ 3,994,924 3,994,924 2,290,639 2,290,639 The interest rates on cash at bank at 30 June 2017 was 1% (2016: between 0.95% to 0.03%) (c) Trade and other payables Current liabilities Trade payables Accrued expenses Other payables Consolidated entity 2017 $ 2016 $ 699,530 568,988 58,044 1,326,562 1,517,255 417,090 52,062 1,986,407 38 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 5 Financial assets and financial liabilities (continued) (d) Other financial liabilities Secured Borrowings Total Borrowings Convertible notes Total Convertible Note Total borrowings Consolidated entity 2017 2016 $ $ 139,864 139,864 772,397 772,397 226,000 1,128,117 226,000 1,128,117 365,864 1,900,514 (i) Convertible note On 17 February 2016, the Company secured AUD$1,700,000 in funding with a New York-based Investment Fund. The facility was being used to fund the immediate start of the clinical phase for IMM-529 in Clostridium difficile. The investment was structured in 3 tranches with a mix of equity financing and convertible securities: • • • Tranche #1 - AUD$100,000 private placement of securities plus a AUD$600,000 repayable Convertible Note with AUD$78,000 finance charge; Tranche #2 - 45 days after issuance of the tranche 1, the Company has the right to call a second Tranche as per Tranche 1 terms. Tranche #3 - by mutual consent, AUD$339,000 Face Value repayable Convertible Note issued on same terms as Tranche 1 and 2. Tranche #3 has not been issued as of the issuance date of the consolidated financial statements. The Convertible Notes are repayable monthly over an 18 month period with each repayment to be settled at Immuron’s discretion by: • • the issuance of new shares at a 10% discount to a 5 Day Volume Weighted Average Price (VWAP) over the 20 trading days immediately prior to a repayment due date; or cash repayment plus a 2.5% premium to the repayment amount. Immuron repaid AUD$902,117 in cash during the 2017 financial year. 39 6 Non-financial assets and liabilities (a) Inventories Current assets Raw materials Work in progress Finished goods Prepaid inventory Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) Consolidated entity 2017 $ 2016 $ 1,793,882 48,425 357,478 136,342 2,336,127 1,259,445 121,513 269,156 405,953 2,056,067 As certain raw materials held by the Company at 30 June 2017 may approach their expiration date for clinical use in the future, management has alternative options to utilise these inventories for R&D, or sale as non-clinical products. There was a $136,494 impairment of inventories recognised during financial year 2017 (2016: $4,176) for stock obsolescence in the Statement of Profit or Loss and Other Comprehensive Income. (b) Other non-financial assets Current assets Prepayments (c) Other non-financial liabilities Deferred revenue (i) Deferred revenue This amount represents amounts billed by the Company for undelivered goods. Consolidated entity 2017 $ 2016 $ 168,366 168,366 74,943 74,943 Consolidated entity 2017 2016 $ 19,139 $ - 40 7 Equity (a) Contributed equity Ordinary shares Ordinary shares - fully paid Total share capital (i) Movements in ordinary share: Opening balance 1 July 2015 Share issued during the year Shares to be issued Treasury shares* Transactions costs Balance 30 June 2016 Share issued during the year Transactions costs Exercise of options - transfer from reserve Balance 30 June 2017 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 2017 Shares 2016 Shares 2017 $ 2016 $ 130,041,417 130,041,417 80,099,646 80,099,646 53,632,995 53,632,995 45,633,354 45,633,354 Notes Number of shares $ 74,964,232 5,135,414 - - - 80,099,646 49,941,771 - - 130,041,417 40,335,347 1,721,789 4,511,378 (800,000) (135,160) 45,633,354 9,965,323 (2,037,557) 71,875 53,632,995 *An adjustment was made in relation to the treasury shares which resulted in a decrease of AUD$800,000 in Non-current assets and Equity as compared to the previous statement lodged with ASX. During the year ended 30 June 2017, the Company issued the following ordinary shares: Date Details 7 July 2016 7 July 2016 29 September 2016 2 December 2016 9 June 2017 issue to oversubscribes and Right issue* Right issue Right private placement Shares under ESOP – for 6 months service (vesting monthly) on issued Shares (equivalent to 610,000 ADSs)** NASDAQ No. 18,045,512 3,275,466 3,968,916 251,877 24,400,000 49,941,771 Issue price $ - 0.250 Total value $ - 818,867 0.250 0.245 0.332 992,229 61,710 8,092,517 9,965,323 *As at 30 June 2016, the Company was committed to issue 18,045,512 of ordinary shares in relation to the $4,511,378 received in capital raising. These shares were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these new fully paid ordinary shares were issued to Grandlodge on the same terms and conditions as all other subscribers. **Grandlodge participated in the NASDAQ IPO and acquired 32,707 ADRs and 32,707 warrants over ADRs (1 ADR is equal to 40 ordinary shares). 41 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 7 Equity (continued) (a) Contributed equity (continued) During the year ended 30 June 2016 the Company issued the following ordinary shares: Date Details 18 September 2015 30 September 2015 19 October 2015 13 November 2015 27 November 2015 24 February 2016 24 February 2016 13 April 2016 18 April 2016 16 May 2016 16 May 2016 31 May 2016 30 June 2016 as for fund Investment Exercise of IMCAI Unlisted Options Exercise of IMCAI Unlisted Options Exercise of IMCAI Unlisted Options by Grandlodge Exercise of IMCAI Unlisted Options Issue of Shares in lieu of cash services payment per the Annual General Resolution 4 of Meeting (AGM) held on 25 Nov 2015 Issue in accordance with executed funding agreement with a New York provider based announced to the ASX on 17 Feb 2016 Issue of fully paid escrow shares as security for any repayment default of the Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider and announced to the ASX on 17 Feb 2016 Issue in accordance with executed funding agreement with a New York based provider announced to the ASX on 17 Feb 2016 First repayment of Convertible Note Security in accordance with executed funding agreement with a New York based provider announced to the ASX on 17 Feb 2016 Exercise of IMCAI Unlisted Options Second repayment of Convertible Note Security in accordance with executed funding agreement with a fund New York based investment provider announced to the ASX on 17 Feb 2016 Issue of Shares in lieu of cash payment for services received Shares to be Issued from Capital Raising as at 30 June 2016 Investment investment fund fund No. 218,750 93,750 556,000 41,666 Issue price $ 0.376 0.376 Total value $ 82,250 35,250 0.376 0.376 209,056 15,667 546,875 0.160 87,500 294,118 0.340 100,000 2,000,000 0.400 800,000 326,797 0.306 100,000 241,764 150,000 0.312 0.276 75,333 41,400 265,694 400,000 0.284 0.250 5,135,414 75,333 100,000 4,511,378 6,233,167 The value of all share based payments of stock is per the terms of an underlying agreement or based on the fair value of the stock on the date of the transaction. (ii) Ordinary shares Ordinary shares have nil par value. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the Company in proportion to the number of and amounts paid on the shares held. 42 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 7 Equity (continued) (a) Contributed equity (continued) On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. (b) Other reserves The following table shows a breakdown of the Statement of Financial Position line item ‘other reserves’ and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table. Options over fully paid ordinary shares Consolidated entity Notes No. of options Amount $ Balance at 1 July 2015 Options issued during the year Options exercised during the year Expense of vested options Lapse of unexercised options Other comprehensive income for the period At 30 June 2016 Restated 16 7,188,676 7,425,532 (1,060,166) - (3,616,413) - 9,937,629 560,646 285,600 (71,875) 1,606,275 (248,345) - 2,132,301 Balance at 1 July 2016 Options/warrants issued during the year Expense of vested options Lapse of unexercised options Other comprehensive income for the period At 30 June 2017 9,937,629 56,002,894 - (2,250,000) - 63,690,523 2,132,301 136,784 333,950 (168,900) - 2,434,135 Foreign currency translation reserve $ (12,581) - - - - 8,846 (3,735) (3,735) - - - 40,017 36,282 Total $ 548,065 285,600 (71,875) 1,606,275 (248,345) 8,846 2,128,566 2,128,566 136,784 333,950 (168,900) 40,017 2,470,417 An adjustment of AUD$1,209,338 was made to the total reserves balance at 30 June 2016 as compared to the previous statement lodged with ASX, as a result of a change in volatility assessment. Effectively, this resulted in an increase in Consulting, Employee and Director Fees expenses and the Loss for the period on the Statement of Profit or Loss and Other Comprehensive income. Refer to note 9(b) for more details. During the year ended 30 June 2017, the Company issued the following options: 43 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 7 Equity (continued) (b) Other reserves (continued) Date Details 7 July 2016 7 July 2016 29 September 2016 9 December 2016 9 June 2017 9 June 2017 13 June 2017 22 June 2017 issue to oversubscribes and Right issue** Right issue Right private placement Unlisted options in lieu of services Options issued to cover equivalent of 610,000 warrants on issue with NASDAQ to be issued to cover Options equivalent of 35,075 warrants with NASDAQ Options issued to cover equivalent of 91,500 warrants issue with NASDAQ Unlisted options in lieu of services on No. 18,045,512 3,275,466 3,968,916 200,000 Issue price* $ - - Total value $ - - - 0.143 - 28,620 24,400,000 0.00033 8,101 1,403,000 0.00033 463 3,660,000 1,050,000 56,002,894 0.00033 0.094 1,215 98,385 136,784 *Issue price has been rounded for presentation of this report. **As at 30 June 2016, the Company was committed to issue 18,045,512 options in relation to the $4,511,378 received in capital raising. These options were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these options were issued to Grandlodge on the same terms and conditions as all other subscribers. On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 27 Nov 2019. These options are currently held in escrow and cannot be exercised until shareholder approval is granted. During the year ended 30 June 2016 the Company issued the following options: Date Details 27 November 2015 18 February 2016 31 May 2016 Issue of Unlisted Options in lieu of cash payment for additional services as per Resolution 5A - 5D of the AGM held on 25 Nov 2015 Issue in accordance with executed funding agreement with a New York based provider announced to the ASX on 17 Feb 2016 Issue of Unlisted Options in lieu of cash payment for services received Investment fund No. Issue price $ Restated Total value $ 6,000,000 - 1,606,275 1,000,000 425,532 7,425,532 0.186 0.235 185,600 100,000 1,891,875 44 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 8 Cash flow information (a) Reconciliation of profit after income tax to net cash inflow from operating activities Profit for the period Adjustment for Add depreciation expense Add back share based payments expense Add back equity issued for non-cash consideration Add change in fair value and interest accrued on borrowings Change in operating assets and liabilities: (Increase) in trade debtors and bills of exchange (Increase) in inventories (Increase) decrease in other operating assets (Decrease) increase in trade creditors Net cash inflow (outflow) from operating activities (b) Non-cash financing and investing activities Consolidated entity 2017 $ 2016 $ (6,804,154) (5,599,004) 4,922 522,665 - 8,561 7,396 (280,060) 69,034 (559,452) (7,031,088) 3,892 1,891,875 187,500 178,401 (1,553,767) (909,800) (30,015) 672,582 (5,158,336) See Note 7 for details on the uncleared funds of $2,612,139 from capital raising as at 30 June 2016. An amount of $162,457 of financed insurance policies and amounts in Accounts Payable as at 30 June 2017 have been charged as transactions costs. An amount of $114,861 of capital raising costs were recognised as expenses but remained unpaid during the period as at 30 June 2016. See Note 16 for details regarding issues of options to employees and for details surrounding the issue of shares to suppliers. 9 Critical estimates, judgements and errors Management evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events are based on current trends and economic data, obtained both externally and within the group. (a) Significant estimates and judgements • • Share-based Payments: The value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares. Refer to note 16 for more details. Impairment of Inventories: The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the ageing of inventories and in particular the shelf life of inventories that affects obsolescence. the provision is assessed by taking into account the recent sales experience, 45 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 9 Critical estimates, judgements and errors (continued) (b) Previously issued Financial Statements Reclassification Subsequent to the issue of the financial statements for the period ended 30 June 2016, for the purpose of the US NASDAQ filing process, management reviewed and re-assessed it’s estimates surrounding the accounting treatment applied to the valuation of Unlisted Options issued in lieu of cash payment during the FY2016 financial year for additional services as per Resolution 5A-5D of the AGM held on 25 Nov 2015. The financial statements for the 30 June 2016 valued the Unlisted Options using the recommended and accepted Black‐Scholes methodology for determining the fair value of the options in accordance with AASB 2 - Share Based Payments. The Company re-assessed the underlying assumptions and estimates surrounding the original Black and Scholes inputs and it was determined that the original volatility input of 42%, was too low. Accordingly, the Company recalculated the value of the Unlisted Options using the Black and Scholes model including a volatility input of 100% which effectively increased the share based payment expense associated with the Unlisted Options. This difference in this valuation pertaining to the FY2016 portion of the Unlisted Option expense was subsequently recorded in the FY2016 financial period effectively restating the original FY2016 presented numbers. 46 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 9 Critical estimates, judgements and errors (continued) (b) Previously issued Financial Statements (continued) Reclassification (continued) The impact on the Consolidated Statement of Comprehensive Income and Consolidated Statement of Financial Position were accordingly restated, as follows: Amounts Reported on ASX 30 June 2016 $ Reassessment of Unlisted Options $ Amounts reported in these financial statements $ Reclassification $ Revenue Sale of goods Total operating revenue Cost of goods sold Gross profit Sales and marketing costs Freight costs Total gross profit less direct selling costs Other income Expenses Consulting, employee and director Corporate administration Depreciation Finance fee costs Impairment of inventory Marketing and promotion Research and development Travel and entertainment expenses Loss before income tax 1,155,523 1,155,523 (301,435) 854,088 (288,227) (134,967) 430,894 3,008,778 (1,630,700) (1,320,570) (3,892) (341,600) (4,176) (487,591) (3,623,961) (416,849) (4,389,667) - - - - - - - - (1,209,337) - - - - - - - (1,209,337) Income tax expense Loss for the period - (4,389,667) - (1,209,337) Other comprehensive income/(loss) for the period, net of tax Total comprehensive loss for the period - - (4,389,667) (1,209,337) Basic/diluted loss per share (cents) 5.7 1.6 (154,446) (154,446) 1,001,077 1,001,077 - (154,446) 154,446 - - - - - - - - - - - - - - - - - (301,435) 699,642 (133,781) (134,967) 430,894 3,008,778 (2,840,037) (1,320,570) (3,892) (341,600) (4,176) (487,591) (3,623,961) (416,849) (5,599,004) - (5,599,004) - (5,599,004) 7.3 47 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 9 Critical estimates, judgements and errors (continued) (b) Previously issued Financial Statements (continued) Reclassification (continued) Amounts Reported on ASX 30 June 2016 $ Reassessment of unlisted options $ Amounts reported in these financial statements $ Reclassification $ Equity Issued capital* Reserves Accumulated losses Total comprehensive loss for the period 46,505,229 847,353 (41,612,019) (871,875) 1,281,213 (1,209,337) 5,740,563 (799,999) - - (1) (1) 45,633,354 2,128,566 (42,821,357) 4,940,563 * A re-classification of Escrow Treasury Shares previously recorded as an Asset has resulted in a $800,000 reduction in the Company’s Assets and a corresponding increase in Company’s equity reserves. There has been some reclassification within the Statement of Cash Flow however, the net effect was not impacted. The re-classification had no impact on the overall results of the Company’s financial statement or position. 10 Financial risk management (a) Financial instruments The Company's financial instruments consist of cash and cash equivalents, trade and other receivables and trade and other payables, borrowing and Convertible note: Consolidated entity 2017 $ 2016 $ 2,290,639 Cash and cash equivalents 4,387,772 Trade and other receivables (1,986,407) Trade and other payables (772,397) Borrowings (1,128,117) Convertible notes The fair values of cash and cash equivalents, trade and other receivables and trade and other payables approximate their carrying amounts largely due to being liquid assets and payables will be settled within 12 months. 3,994,924 1,768,237 (1,326,562) (139,864) (226,000) (b) Risk management policy The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Company's implementation of that system on a regular basis. The Board and Senior Management identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review of: • • • • the major risks that occur within the business; the degree of risk involved; the current approach to managing the risk; and if appropriate, determine: • • any inadequacies of the current approach; and possible new approaches that more efficiently and effectively address the risk. 48 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 10 Financial risk management (continued) (b) Risk management policy (continued) Management report risks identified to the Board through the monthly Operations Report. The Company seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimised in a cost effective manner. (c) Significant accounting policies Details of significant accounting policies and methods adopted, including the criteria for recognition, the basis for measurement and the basis on which income and expenses are recognised, in respect of each class of financial asset, financial liability and equity instrument are disclosed in Note 20 to the financial statements. The carrying amounts of cash and cash equivalents, trade and other receivables, trade and other payables and financial liabilities represents their fair values determined in accordance with the accounting policies disclosed in Note 20. Interest income on cash and cash equivalents is disclosed in Note 5(a). (d) Capital risk management The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern and to maintain an optimal capital structure so as to maximise shareholder value. In order to maintain or achieve an optimal capital structure, the Company may issue new shares or reduce its capital, subject to the provisions of the Company's constitution. The capital structure of the Company consists of equity attributed to equity holders of the Company, comprising contributed equity, reserves and accumulated losses disclosed in Notes 7(a) and 7(b). By monitoring undiscounted cash flow forecasts and actual cash flows provided to the Board by the Company's Management the Board monitors the need to raise additional equity from the equity markets. (i) Financial risk management The main risks the Company is exposed to through its operations are interest rate risk, foreign exchange risk, credit risk and liquidity risk. Interest rate risk (ii) The Company is exposed to interest rate risks via the cash and cash equivalents and borrowings that it holds. Interest rate risk is the risk that a financial instruments value will fluctuate as a result of changes in market interest rates. The objective of managing interest rate risk is to minimise the Company's exposure to fluctuations in interest rate that might impact its interest revenue and cash flow. Interest rate risk is considered when placing funds on term deposits. The Company considers the reduced interest rate received by retaining cash and cash equivalents in the Company's operating account compared to placing funds into a term deposit. This consideration also takes into account the costs associated with breaking a term deposit should early access to cash and cash equivalents be required. There has been no change to the Company's exposure to interest rate risk or the manner in which it manages and measures its risk in the year ended 30 June 2017. (iii) Foreign currency risk The Company is exposed to foreign currency risk via the trade and other receivables and trade and other payables that it holds. Foreign currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company aims to take a conservative position in relation to foreign currency risk hedging when budgeting for overseas expenditure however, the Company does not have a policy to hedge overseas payments or receivables as they are highly variable in amount and timing, due to the reliance on activities carried out by overseas entities and their billing cycle. 49 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 10 Financial risk management (continued) (d) Capital risk management (continued) The following financial assets and liabilities are subject to foreign currency risk: Cash and cash equivalent (AUD/USD) Trade and other receivable (AUD/USD) Trade and other payables (AUD/USD) Trade and other payables (AUD/CHF) Trade and other payables (AUD/NZD) Trade and other payables (AUD/ISL) Consolidated entity 2017 $ 2,770,682 126,207 502,651 - - 20,489 2016 $ 40,702 127,110 564,104 10,069 452,599 46,260 Foreign Currency purchase: On 25 August 2016 on behalf of Immuron, Grandlodge purchased US$1,500,000 at the cost of AUD$1,968,762. On the same day Immuron paid Grandlodge AUD$1,968,762 to settle this transaction. On 12 September 2016 Grandlodge returned the USD$1,500,000 purchase to Immuron. Grandlodge received no financial gains or benefits from this transaction. Foreign currency risk is measured by regular review of cash forecasts, monitoring the dollar amount and currencies that payment are anticipated to be paid in. The Company also considers the market fluctuations in relevant currencies to determine the level of exposure. If the level of exposure is considered by Management to be too high, then Management has authority to take steps to reduce the risk. Steps to reduce risk may include the acquisition of foreign currency ahead of the anticipated due date of an invoice, or may include negotiations with suppliers to make payment in our functional currency, or may include holding receipted foreign currency funds in a foreign currency denominated bank account to make future payments denominated in that same currency. Should Management determine that the Company consider taking out a hedge to reduce the foreign currency risk, they would need to seek Board approval. The Company conducts some activities outside of Australia which exposes it movements, where the Company is required to pay in a currency other than its functional currency. to transactional currency There has been no change in the manner the Company manages and measures its risk in the year ended 30 June 2017. The Company is exposed to fluctuations in the United States dollars and Israeli Shekel. Analysis is conducted on a currency by currency basis using sensitivity variables. The Company has conducted a sensitivity analysis of the Company's exposure to foreign currency risk. The analysis shows that if the Company's exposure to foreign currency risk was to fluctuate as disclosed below and all other variables had remained constant, then the foreign currency sensitivity impact on the Company's loss after tax and equity would be as follows: 50 10 Financial risk management (continued) (d) Capital risk management (continued) AUD/US: 2017 + 8.00% (2016: + 8.00%) AUD/US: 2017 - 8.00% (2016: - 8.00%) AUD/CHF: 2017 + 11.00% (2016: + 11.00%) AUD/CHF: 2017 - 11.00% (2016: - 11.00%) AUD/NZD: 2017 + 11.00% (2016: + 11.00%) AUD/NZD: 2017 - 11.00% (2016: - 11.00%) AUD/ISL: 2017 + 11.00% (2016: + 11.00%) AUD/ISL: 2017 - 11.00% (2016: - 11.00%) Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) Consolidated entity 2017 (Higher) / Lower $ 35,186 (35,186) - - - - 2,254 (2,254) 2016 (Higher) / Lower $ 45,128 (45,128) 1,108 (1,108) 49,786 (49,786) 5,089 (5,089) (iv) Credit risk The Company is exposed to credit risk via its cash and cash equivalents and trade and other receivables. Credit risk is the risk that a counter-party will default on its contractual obligations resulting in a financial loss to the Company. To reduce risk exposure for the Company's cash and cash equivalents, it places them with high credit quality financial institutions. The Company’s major ongoing customers are the large pharmaceutical companies for the distribution of Travelan and other Hyperimmune products, and Government bodies for the receipt of GST refunds and Research and Development Tax Concession amounts due to the Company from the Australian Tax Office. The Company has a policy that limits the credit exposure to customers and regularly monitors its credit exposure. The Board believes that the Company does not have significant credit risk at this time in respect of its trade and other receivables. Regarding customers with over 30-day debt balance, management has maintained on-going communication with relevant counter parties in regard of repayment schedule, and concluded that there have been no changes to the initial assessment of credit risk. The Company has analysed its trade and other receivables below: Consolidated entity 2017 Trade and other receivables R&D tax concession refund Total 2016 Trade and other receivables R&D tax concession refund Total 0 - 30 days AUD$ 31 - 60 days AUD$ 61 - 90 days AUD$ 90 + days AUD$ Total AUD$ 173,248 - 173,248 2,822,116 - 2,822,116 33,731 - 33,731 45,687 - 45,687 419 - 419 - - - 62,727 - 62,727 540,250 1,498,112 2,038,362 7,129 - 7,129 5,749,864 1,512,840 7,262,704 R&D tax concession refund in each period is recovered upon finalization of the Australian Tax Office’s review of the Company’s annual R&D tax concession claim. (v) Liquidity risk The Company is exposed to liquidity risk via its trade and other payables and its recurring and projected losses. 51 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 10 Financial risk management (continued) (d) Capital risk management (continued) Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet the commitments associated with its financial instruments. Responsibility for liquidity risk rests with the Board who manage liquidity risk by monitoring undiscounted cash flow forecasts and actual cash flows provided to them by the Company's Management at Board meetings to ensure that the Company continues to be able to meet its debts as and when they fall due. Contracts are not entered into unless the Board believes that there is sufficient cash flow to fund the additional activity. The Board considers when reviewing its undiscounted cash flow forecasts whether the Company needs to raise additional funding from the equity markets. The Company has analysed its trade and other payables below: Consolidated entity 2017 Trade and other payables Borrowings Convertible note Total 2016 Trade and other payables Borrowings Convertible note Total 0 - 30 days AUD$ 31 - 60 days AUD$ 61 - 90 days AUD$ 90 + days AUD$ Total AUD$ 1,074,569 - - 1,074,569 1,008,089 - - 1,008,089 102,546 - - 102,546 659,494 - - 659,494 72,052 - - 72,052 299,239 - - 299,239 77,395 - - 77,395 19,585 - - 19,585 1,326,562 139,864 226,000 1,692,426 1,986,407 772,397 1,128,117 3,886,921 As at 30 June 2017, the Company maintained a cash and cash equivalents balance of AUD$3,994,924. Additionally, the Company also recognised a total of AUD$1,768,237 in receivables, including AUD$1,498,112 related to R&D Tax Concession, which will be received in the near future. On this basis, even though the Company has been in loss making position historically, management is satisfied that the Company is a going concern and are of the opinion that no asset is likely to be realized for an amount lower than the amount at which it is recorded in the Consolidated Statement of Financial Position at 30 June 2017. 11 Interests in other entities (a) Subsidiaries The Company's subsidiaries at 30 June 2017 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or registration is also their principal place of business. Name of entity Immuron Inc. Anadis EPS Pty Ltd Place of business/ country of incorporation USA Australia Ownership interest held by the Company 2017 % 100.0 100.0 2016 % 100.0 100.0 52 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 11 Interests in other entities (continued) (a) Subsidiaries (continued) These companies are wholly owned subsidiary of Immuron Limited and was formed for the sole purpose to act as trustee for the Immuron Limited Executive Officer Share Plan Trust. All costs associated with the operations of this company are borne by Immuron Limited. Consolidated accounts have not been prepared as the net assets and trading activity of Anadis ESP Pty Ltd are not material. 12 Contingent liabilities and contingent assets There has been no change in contingent liabilities and assets since the last annual reporting date. 13 Commitments (a) Non-cancellable operating leases Commitments for minimum lease payments in relation to non-cancellable operating leases are payable as follows: Within one year Later than one year but not later than five years Consolidated entity 2017 $ 39,524 19,762 59,286 The property lease is a non-cancellable lease with a 3 year term, with rent payable monthly in advance. The minimum lease payments shall be increased by CPI per annum. An option exists to renew the lease at the end of the 3 year term for an additional term of 3 years. The current lease period expires in December 2018. The Group has recognised $46,082 and $25,501, of rental expenses in its Statement of Profit or Loss and Other Comprehensive Income for the year 2017 and 2016, respectively, as Corporate Administration Expense. 14 Events occurring after the reporting period 28 July 2017 - The Company issued 399,045 fully paid ordinary shares for repayment of $75,333 Convertible Note Security in accordance with executed funding agreement with a New York based Investment funds provider announced to the ASX on 17 February 2017. 3 Aug 2017 - The Company announced the resignation of Mr Thomas Liquard and the appointment of Dr Jerry Kanellos as the interim CEO. Immuron’s Chief Operating and Scientific Officer Dr Jerry Kanellos assumed the role of Interim-Chief Executive Officer from 1 August 2017. For Dr Kanellos’ increased role at Immuron his total remuneration package has increased to $230,000 per annum. Dr Kanellos’ contract has a 30-day termination notice period. Other than the events listed above, there have not been any other matters or circumstances in the financial statements or notes thereto, that have arisen since the end of the financial year which significantly affected, or may significantly affect, the operations of Immuron Limited. 15 Related party transactions (a) Key management personnel compensation This note details the nature and amount of remuneration for each Director of Immuron Limited, and for the Key Management Personnel. 53 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 15 Related party transactions (continued) (a) Key management personnel compensation (continued) The Directors of Immuron Limited during the year ended 30 June 2017 were: The following persons held office as Directors of Immuron Limited during the financial year: Dr. Roger Aston, Independent non-executive chairman Mr. Peter Anastasiou, Executive vice chairman Mr. Daniel Pollock, Independent non-executive director Mr. Stephen Anastasiou, Independent non-executive director Prof. Ravi Savarirayan, Independent non-executive director (appointed 7 April 2017) The following persons held office as Key Management Personnel of Immuron Limited during the financial year with the following changes subsequent to 30 June 2017: Dr. Jerry Kenellos, Interim Chief Executive Officer (CEO), (appointed 3 August 2017) and Chief Operating & Scientific Officer (COSO) Mr. Thomas Liquard, Chief Executive Officer (CEO), (resigned 3 August 2017) The aggregate compensation made to Directors and Other Key Management Personnel of the Company is set out below: Short-term employee benefits Post-employment benefits Share-based payments Consolidated entity 2017 $ Restated 2016 $ 681,666 25,947 353,670 1,061,283 652,514 26,004 1,606,275 2,284,793 Detailed remuneration disclosures are provided in the remuneration report on pages 20 to 29. 54 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 15 Related party transactions (continued) (b) Transactions with other related parties The following transactions occurred with related parties: Short-term loan from Grandlodge Capital Pty Ltd: Grandlodge Capital Pty Ltd (Grandlodge) is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Mr David Plush is also an owner of Grandlodge, and its associated entities. On 1 December 2015, 6 June 2016 and 9 May 2017, Immuron executed a short-term funding agreement with Grandlodge for a principle amount of $1,000,000 (interest rate 15%) and $500,000 (interest rate 15%) respectively. rate 13%), $750,000 (interest receive from the Australian Taxation Office under The short-term funding is a cash advance against the anticipated refund Immuron will the Research and Development Income Tax Concession Incentive for the Company's eligible R&D expenditure incurred for financial year of 2016 and 2017. Loan from December 2016, June 2016 and May 2017, plus applicable fees and interest, was repaid to Grandlodge on 10 February 2016, 2 December 2016 and 23 June 2017, respectively. Interest expense was approximately $57,000 and $31,000 for the years ended 30 June 2017 and 2016, respectively. In addition, the Company incurred approximately $35,000 of loan fees for the year ended 30 June 2016. Total paid by the Company to Grandlodge Pty Ltd during the year: At year end the Company owed Grandlodge Pty Ltd: Premises rental services received from Wattle Laboratories Pty Ltd to Immuron Limited: Wattle Laboratories Pty Ltd (Wattle) is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Commencing on 1 January 2016, Immuron executed a Lease Agreement with Wattle whereby Immuron will lease part of their Blackburn office facilities for Immuron's operations at an arms-length commercial rental rate of $38,940 per annum, payable in monthly instalments. The rental agreement is subject to annual rental increases, and effective 1 January 2017, the annual rent was increased to $39,525. The lease is for a 3 year term with an additional 3 year option period. The lease is cancellable by either party upon 6 months written notice of termination of the agreement. Rental fees paid to Wattle Laboratories Pty Ltd during the year through the issue of equity: Total paid by the Company to Wattle Laboratories Pty Ltd during the year: At year end the Company owed Wattle Laboratories Pty Ltd: 55 30 June 2017 30 June 2016 $1,329,007 $Nil $1,043,863 $772,397 30 June 2017 30 June 2016 $Nil $Nil $35,792 $19,470 $Nil $21,417 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 15 Related party transactions (continued) (b) Transactions with other related parties (continued) Service rendered by Grandlodge Pty Ltd to Immuron Ltd: Grandlodge, and its associated entities, are marketing, warehousing and distribution logistics companies. 30 June 2017 30 June 2016 Commencing on 1 June 2013, Grandlodge was contracted on commercial market arms-length terms to provide warehousing, distribution and invoicing services for Immuron’s products for $70,000 per annum. These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price of $0.16 per share representing Immuron Limited’s share price at the commencement of the agreement. The shares to be issued to Grandlodge, or its associated entities, as compensation in lieu of cash payment for the services rendered under this agreement have been subject to the approval of Immuron shareholders at Company shareholder meetings held over the past 18 months. Grandlodge will also be reimbursed in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the agreement, unless both parties agree to an alternative method of payment. The agreement is cancellable by either party upon providing the other party with 30 days written notice of the termination of the agreement. Service fees paid to Grandlodge Pty Ltd during the year through the issue of equity: Total paid by the Company to Grandlodge Pty Ltd during the year: At year end the Company owed Grandlodge Pty Ltd: $Nil $87,500 $Nil $105,000 $87,500 $35,000 Foreign Currency purchase: On 25 August 2016 on behalf of Immuron, Grandlodge purchased US$1,500,000 at the cost of AUD$1,968,762. On the same day Immuron paid Grandlodge AUD$1,968,762 to settle this transaction. On 12 September 2016 Grandlodge returned the USD$1,500,000 purchase to Immuron. Grandlodge received no financial gains or benefits from this transaction. 56 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 16 Share-based payments Executives and consultants may be provided with longer-term incentives through the Company’s Employee Share and Option Plan (ESOP), to allow the executives and consultants to participate in, and benefit from, the growth of the Company as a result of their efforts and to assist in motivating and retaining these key employees over the long term. (a) Options issued under ESOP The following table illustrates the number and weighted average exercise price of and movement in share options issued under the scheme during the year: Consolidated entity 2017 2016 As at 1 July Granted during the year Exercised during the year Lapse of unexercised options As at 30 June Vested and exercisable at 30 June Weighted Average exercise price per share option 1.56 0.50 - 0.50 0.55 0.55 Weighted Average exercise price per share option 0.44 - 0.28 0.28 0.56 1.56 Number of options 1,062,500 1,250,000 - (1,000,000) 1,312,500 1,312,500 Number of options 1,856,150 - (150,000) (643,650) 1,062,500 62,500 The options outstanding at 30 June 2017 have a weighted average remaining contractual life of 1.39 years (2016: 0.79 years) and exercise prices ranging from $0.50 to $1.56 (2016: from $0.50 to $1.556). (b) Options issued to directors The following table illustrates the number and weighted average exercise price of and movement in share options issued to directors during the year: Consolidated entity 2017 2016 As at 1 July Granted during the year Lapse of unexercised options As at 30 June Vested and exercisable at 30 June Weighted Average exercise price per share option 0.46 - 0.46 0.50 0.50 Weighted Average exercise price per share option 0.46 0.50 - 0.49 0.46 Number of options 7,000,000 - (1,000,000) 6,000,000 5,000,000 Number of options 1,000,000 6,000,000 - 7,000,000 1,000,000 The options outstanding at 30 June 2017 have a weighted average remaining contractual life of 2.41 years (2016: 2.94 years) and exercise price of $0.50 (2016: $0.50). On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 27 Nov 2019. These options are currently held in escrow and cannot be exercised until shareholder approval is granted. 57 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 16 Share-based payments (continued) (c) Other options/warrants issued The following table illustrates the number and weighted average exercise price of and movement in share options issued to other parties during the year: Consolidated entity As at 1 July Granted during the year Exercised during the year Lapse of unexercised options As at 30 June Vested and exercisable at 30 June 2017 Average exercise price per share option 0.56 0.43 - 0.46 0.44 0.44 2016 Average exercise price per share option 0.40 0.55 0.38 0.38 0.56 0.56 Number of options 4,332,526 1,425,532 (910,166) (2,972,763) 1,875,129 1,875,129 Number of options 1,875,129 54,752,894 - (250,000) 56,378,023 56,378,023 The options outstanding at 30 June 2017 have a weighted average remaining contractual life of 3.57 years (2016: 2.85 years) and exercise prices ranging from $0.30 to $1.94 (2016:from $0.30 to $1.944). (d) Vesting terms of options The following summarises information about options held by employees, directors and third parties as at 30 June 2017: Grant date a 29-Jun-12 29-Jun-12 15-Nov-12 3-Mar-14 29-May-14 27-Nov-15 18-Feb-16 31-May-16 7-Jul-16 9-Dec-16 9-Jun-17 13-Jun-17 22-Jun-17 Number of options Vesting conditions 14,493 29,668 62,500 15,380 140,056 6,000,000 1,000,000 425,532 25,289,894 200,000 24,400,000 3,660,000 1,050,000 Nil Nil 25% per annum Nil Nil See below Nil Nil Nil Nil Nil Nil Nil Expiry date Exercise price $ 30-Nov-21 17-Jan-22 1-Nov-17 28-Feb-19 28-May-19 27-Nov-19 24-Feb-19 27-Nov-19 30-Nov-19 27-Nov-19 13-Jun-22 13-Jun-22 1-Oct-18 1.944 1.876 1.556 1.892 0.300 0.500 0.570 0.500 0.550 0.500 0.326 0.326 0.500 58 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 16 Share-based payments (continued) (d) Vesting terms of options (continued) In addition, the Company accrued and issued the below equity that is not presented in the above table: • On 9 June 2017, the Company accrued 1,403,000 Options to be issued to cover equivalent of 35,075 warrants with NASDAQ. • On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 27 Nov 2019. These options are currently held in escrow and cannot be exercised until shareholder approval is granted. (i) November 2012 options The options with an issue date of 15 November 2012, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of $1.556*. There are no performance conditions attached to the options as the options vest accordingly to the following anniversary dates: • • • • 25% of the total quantum of these options issued vested immediately upon issue 25% of the total quantum of these options issued vest on 1 July 2013 25% of the total quantum of these options issued vest on 1 July 2014 25% of the total quantum of these options issued vest on 1 July 2015 (ii) December 2013 Options The options with an issue date of 4 December 2013, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.456*. There are no performance conditions attached to the options. The options were deemed to have been fully vested on their date on issue. (iii) November 2015 options The options with an issue date of 27 November 2015, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of $0.500. Options vest based on month of continuous services completed as per the following: • • 5,000,000 Options which vested on 6 August 2016 - subject to completion of 12 months’ continuous services as a Director of the Company 1,000,000 Options which vested on 6 August 2017 - subject to completion of 24 months’ continuous services as a Director of the Company (iv) February 2016 options The options with an issue date of 18 February 2016, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of $0.570. There are no performance conditions attached to the options. The options were deemed to have been fully vested on their date on issue. (v) May 2016 options The options with an issue date of 31 May 2016, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of $0.500. There are no performance conditions attached to the options. The options were deemed to have been fully vested on their date on issue. (vi) December 2016 options Pursuant to an agreement entered between the Company and a consultant on 1 April 2015, the Company granted 1,000,000 options, which became vested and issued on 9 December 2016, and entitled the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.500. These options were vested and issued following the successful completion of related milestone pertaining to a minimum recruitment of 100 patients into the Company's NASH Phase IIb clinical trial. 59 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 16 Share-based payments (continued) (d) Vesting terms of options (continued) (vii) June 2017 options The options with various issue dates in June 2017, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price ranging from $0.326 to $0.500. There are no performance conditions attached to the options. The options were deemed to have been fully vested on their date on issue. *The above values has been adjusted for 40:1 share consolidation which was completed on 20 November 2014. (e) Deemed valuation of options The fair value of the options granted by the Company under the Company’s Executive Share and Option Plan (ESOP) is estimated as at the grant date using Black-Scholes model taking into account the terms and conditions upon which the options were granted. (i) November 2012 options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date Dividend yield Expected volatility Risk-free interest rate Expected life of option (years) Option exercise price Weighted average share price at grant date Value per option As per above - 70% 3.25% 5.00 $0.04 $0.017 $0.280* *The above values have been adjusted for 40:1 share consolidation which was completed on 20 November 2014. (ii) December 2013 options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date Dividend yield Expected volatility Risk-free interest rate Expected life of option (years) Option exercise price Weighted average share price at grant date Value per option N/A - 62% 3.03% 3.00 $0.01 $0.01 $0.1016* *The above values have been adjusted for 40:1 share consolidation which was completed on 20 November 2014. (iii) November 2015 options (Restated) The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date Dividend yield Expected volatility Risk-free interest rate Expected life of option (years) Option exercise price Weighted average share price at grant date Value per option As per above - 100% 2.11% 4.00 $0.500 $0.465 $0.3186 60 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 16 Share-based payments (continued) (e) Deemed valuation of options (continued) (iv) February 2016 options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date Dividend yield Expected volatility Risk-free interest rate Expected life of option (years) Option exercise price Weighted average share price at grant date Value per option N/A - 97% 1.73% 3.00 $0.570 $0.360 $0.1856 (v) May 2016 options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date Dividend yield Expected volatility Risk-free interest rate Expected life of option (years) Option exercise price Weighted average share price at grant date Value per option N/A - 84% 2.11% 4.00 $0.500 $0.410 $0.235 (vi) December 2016 options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date Dividend yield Expected volatility Risk-free interest rate Expected life of option (years) Option exercise price Weighted average share price at grant date Value per option N/A - 100% 1.61% 3.17 $0.500 $0.285 $0.1431 (vii) June 2017 options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date Dividend yield Expected volatility Risk-free interest rate Expected life of option (years) Option exercise price Weighted average share price at grant date Value per option n/a - 100% 1.69% 1.33 $0.500 $0.315 $0.0937 At 30 June 2016 the Australian Securities Exchange (ASX) market share price for Immuron was $0.250. At 30 June 2017 the Australian Securities Exchange (ASX) market share price for Immuron was $0.270. 61 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 16 Share-based payments (continued) (e) Deemed valuation of options (continued) The expected life of the option is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. 17 Remuneration of auditors During the year the following fees were paid or payable for services provided by the auditor of the Parent entity, its related practices and non-related audit firms: (a) Auditor firm (i) Audit and other assurance services Audit and other assurance services Audit and review of financial statements - William Buck Audit and review of financial statements - Marcum Other assurance services NASDAQ Listing services - Marcum Total remuneration for audit and other assurance services Consolidated entity 2017 $ 2016 $ 41,600 91,175 470,503 603,278 36,100 - - 36,100 During the year, the Company had engaged its US auditor Marcum LLP to assist with filing of the F-1 application form for listing on the NASDAQ exchange in the USA. Total fees charged for these services were AUD $470,503 (2016: $Nil). The directors are satisfied that the provision of these services is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The nature and scope of the audit services provided means that auditor independence was not compromised. 18 Loss per share (a) Basic/diluted loss per share Consolidated entity 2017 Cents Restated 2016 Cents From continuing operations attributable to the ordinary equity holders of the company (6.4) (7.3) (b) Reconciliation of earnings used in calculating loss per share Consolidated entity 2017 $ Restated 2016 $ Loss attributable to the ordinary equity holders of the Company used in calculating basic/diluted loss per share: (6,804,154) (5,599,004) 62 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 18 Loss per share (continued) (c) Weighted average number of shares used as the denominator Consolidated entity 2017 Number 2016 Number* Weighted average number of ordinary shares used as the denominator in calculating basic/diluted loss per share 105,866,110 76,435,993 * This amount includes 182,169 of weighted average ordinary shares in relation to the $4,511,378 received in capital raising that was not issued as of 30 June 2016. The Company is currently in a loss making position any thus the impact of any potential shares is concluded as anti-dilutive which includes the company’s options and Convertible Note payable and warrants. Treasury shares are excluded from the calculation of weighted average number of ordinary shares. 19 Parent entity financial information (a) Summary financial information The individual financial statements for the Parent entity show the following aggregate amounts: Balance sheet Current assets Non-current assets Total assets Current liabilities Shareholders' equity Issued capital Retained earnings Profit or loss for the period (b) Contingent liabilities of the parent entity 2017 $ 2016 $ 8,211,562 1,659,635 9,871,197 1,707,924 (8,163,273) 8,799,844 891,794 9,691,638 3,886,922 (5,804,716) 53,632,996 (47,903,858) 45,633,353 (41,960,938) 5,729,138 3,672,415 (6,039,941) (4,885,381) The Parent entity did not have any contingent liabilities as at 30 June 2017 or 30 June 2016. For information about guarantees given by the Parent entity, please see above. (c) Determining the parent entity financial information The financial information for the Parent entity has been prepared on the same basis as the consolidated financial statements, except as set out below. Investments in subsidiaries, associates and joint venture entities (i) Investments in subsidiaries, associates and joint venture entities are accounted for at cost in the financial statements of Immuron Limited. 63 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 19 Parent entity financial information (continued) (c) Determining the parent entity financial information (continued) (ii) Tax consolidation legislation Immuron Limited and its wholly-owned Australian controlled entities have implemented the tax consolidation legislation. The head entity, Immuron Limited, and the controlled entities in the tax consolidated Company account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated Company continues to be a stand-alone taxpayer in its own right. In addition to its own current and deferred tax amounts, Immuron Limited also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated Company. 20 Summary of significant accounting policies (a) Corporate Information The consolidated financial statements Immuron Limited (‘the Company’) and the entities it controlled for the year ended 30 June 2017 was authorised for issue in accordance with a resolution of the Directors on Thursday, 28 September 2017. Immuron Limited is a listed public company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (ASX) and NASDAQ. The principal activity of the Company is a product development driven biopharmaceutical Company focused on the research and development of polyclonal antibodies for the treatment and prevention of major diseases. (b) Basis of preparation The financial report is a general-purpose financial report, which has been prepared in accordance with the requirements of Australian Accounting Standards ("AAS's"), required for a for-profit entity. The financial report has been prepared on an accruals basis and is based primarily on historical costs. The financial report is presented in Australian dollars, which is the Company’s functional and presentation currency. All values are rounded to the nearest dollar unless otherwise stated. Management is required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstance, the results of which form the basis of making the judgements. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Judgements made by management in the application of IFRS that have significant effects on the financial statements and estimates with a significant risk of material adjustments in the next year are disclosed, where applicable, in the relevant notes to the financial statements. Accounting policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance and reliability, the underlying transactions or other events is reported. thereby ensuring that the substance of (i) Compliance with IFRS The consolidated financial statements of Immuron Limited also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). 64 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 20 Summary of significant accounting policies (continued) (b) Basis of preparation (continued) (ii) New and amended standards adopted by the Company All accounting policies adopted are consistent with the most recent Annual Financial Report for the year ended 30 June 2016. The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretation issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet effective and have not been adopted by the Company for the annual reporting period ending 30 June 2017 are outlined in the table below. Standard AASB 2016-1 Amendments to Australian Accounting Standards - Recognition of Deferred Tax Assets for Unrealised Losses AASB 2016-2 Amendments to Australian Accounting Standards - Disclosure Initiative: Amendments to AASB 107 AASB 2017-2 Amendments to Australian Accounting Standards - Further Annual Improvements 2014-2016 Cycle AASB 9 Financial Instruments and related standards AASB 15 Revenue from Contracts with Customers and AASB 2014-5 Amendments to Australian. Accounting Standards arising from AASB 15 AASB 2016-3 Amendments to Australian Accounting Standards - Clarifications to AASB 15 AASB 2016-5 Amendments to Australian Accounting Standards - Classification and Measurement of Share-based Payment Transactions IFRIC 23 Uncertainty over Income Tax Treatments AASB 16 - Leases Mandatory date for annual reporting periods (beginning on or after) 1 January 2017 Reporting period standard adopted by the company 1 July 2017 1 January 2017 1 July 2017 1 January 2017 1 July 2017 1 January 2018 1 January 2018 1 July 2018 1 July 2018 1 January 2018 1 July 2018 1 January 2018 1 July 2018 1 January 2019 1 January 2019 1 July 2019 1 July 2019 Management are currently assessing the impact of these new standards on the Company and have commenced an analysis on the impact of AASB 15 - Revenue from Contracts with Customers. At the date of writing whilst management does not expect this standard to have a material effect on the position of the Company, the potential impacts of this change are still being fully assessed. (c) Accounting policies The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated. Basis of consolidation The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries) referred to as ‘the Group’ in the financial statements. Control is achieved where the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases. 65 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 20 Summary of significant accounting policies (continued) (c) Accounting policies (continued) Basis of consolidation (continued) A list of controlled entities is contained in Note 11 to the financial statements. All controlled entities have a 30 June financial year-end. All intra-group transactions, balances, income and expenses are eliminated in full on consolidation. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with those policies applied by the parent entity. Subsidiaries are accounted for at cost in the parent entity. The results of subsidiaries acquired or disposed of during the year are included in profit or loss from the effective date of acquisition or up to the effective date of disposal, as appropriate. Segment reporting The Company determines and presents operating segments using the ‘management approach’ where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM are responsible for the allocation of resources to operating segments and assessing their performance and provide the strategic direction and management oversight of the day to day activities of for research and development expenditure decisions and challenging and approving strategic planning for the business. the entity in terms of monitoring results, providing approval Foreign currency translation (i) Functional and presentation currency Items included in the financial statements are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The financial statements are presented in Australian dollars, which is the Company’s functional and presentation currency. (ii) Transactions and balances Transactions in foreign currencies are translated into the functional currency using the rates of exchange ruling at the date of each transaction. At reporting date, amounts outstanding in foreign currencies are translated into the functional currency using the rate of exchange ruling at the end of the financial year. Refer to Note 3 for the foreign currency gains and losses recognized during the periods. Foreign exchange gains and losses that relate to borrowings are presented in the statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit or loss and other comprehensive income on a net basis within Corporate Administration Costs. Immuron Inc., a subsidiary of the Group, has USD as its functional currency. Accordingly, this entity’s statement of comprehensive income and statement of financial position balances have been translated to the Group’s presentation currency (which is AUD$) at the reporting date. A gain arising from this translation of AUD$40,017 (2016: AUD$8,846) are recognized as Other Comprehensive Income for the year. Revenue recognition Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. The Company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the Company's activities as described in note 2. The amount of the revenue is not considered to be reliably measured until all contingencies relating to the sale have been resolved. 66 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 20 Summary of significant accounting policies (continued) (c) Accounting policies (continued) Revenue recognition (continued) The following specific revenue criteria must be met before revenue is recognized: (i) Sale of Goods and services Significant risks and rewards of ownership of goods has passed to the buyer and an invoice for the goods or services is issued; Interest income (ii) Interest income is recognized using the effective interest rate method; (iii) R & D Tax Refund Income is recognized in the year the research and development expenses were incurred. The Company has worked with experienced advisors to improve its internal process on advanced findings of the R&D activities, which includes determining and evaluating the eligibility of R&D related expenditure to support its submission of the R&D Tax Refund claim. Government grants Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and the Company will comply with all attached conditions. Government grants relating to costs to be incurred are deferred or accrued such that they are recognized in the statement of profit or loss and other comprehensive income over the period necessary to match them with the costs that they are intended to compensate. Income tax The income tax expense or revenue for the period is the tax payable or tax rebate receivable on the current period’s taxable income adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax base of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses. Deferred income tax is provided in full, using the liability method on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither the accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of reporting period and are expected to apply when the related deferred income tax is realized or the deferred income tax liability is settled. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Current and deferred tax balances attributable to amounts recognized directly in equity are also recognized directly in equity. 67 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 20 Summary of significant accounting policies (continued) (c) Accounting policies (continued) Impairment of non-financial assets Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use. Cash and cash equivalents For presentation purposes, cash and cash equivalents includes cash on hand. Trade receivables Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method, less provision for impairment. Trade receivables are due for settlement no more than 30 days from the date of recognition. Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for impairment of trade receivables is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of receivables. financial difficulties of the debtor, probability that Significant the debtor will enter bankruptcy or financial reorganisation and default or delinquency in payment (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The amount of the provision is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short term receivables are not discounted if the effect of discounting is immaterial. The amount of the provision is recognized in the statement of profit or loss and other comprehensive income. Inventories (i) Raw materials, work in progress and finished goods Raw materials, work in progress and finished goods are stated at the lower of cost and net realisable value. Where appropriate, cost comprises direct materials, direct labor and an appropriate proportion of variable and fixed overheads expenditure, the latter being allocated on the basis of normal operating capacity. The Company classifies inventory as a current asset as all amounts are held for the purpose of trading. Costs are assigned to individual items of inventory on basis of weighted average costs. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Plant and equipment Plant and equipment are stated at historical cost expenditure that is directly attributable to the acquisition of the items. less accumulated depreciation. Historical cost includes Repairs and maintenance are charged to the statement of profit or loss and other comprehensive income during the financial period in which they are incurred. Depreciation on assets is calculated using the straight line method to allocate their cost, net of their residual values, over their estimated useful lives, as follows: Plant & Equipment (3-15 years) Computer Equipment (2-4 years) Furniture & Fittings (3-15 years) The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, annually. 68 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 20 Summary of significant accounting policies (continued) (c) Accounting policies (continued) Plant and equipment (continued) An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the statement of profit or loss and other comprehensive income. Intangible assets (i) Research and development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits and adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the statement of profit or loss and other comprehensive income as an expense as incurred. Trade and other payables These amounts represent liabilities for goods and services provided to the entity prior to the end of the financial year and which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method. Employee benefits (i) Short-term obligations Liabilities for wages and salaries, annual leave and long service leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. (ii) Other long-term employee benefit obligations The liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. The obligations are presented as current liabilities in the Statement of financial position if the entity does twelve months after the reporting period, for at not have an unconditional right regardless of when the actual settlement is expected to occur. to defer settlement least (iii) Retirement benefit obligations Contributions to the defined contribution superannuation funds are recognized as an expense as they become payable. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. 69 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 20 Summary of significant accounting policies (continued) (c) Accounting policies (continued) Employee benefits (continued) (iv) Share-based payments Share-based compensation benefits may be provided through the issue of fully paid ordinary shares under the Immuron Employee Share and Option Plan. Options are also granted to employees and consultants in accordance with the terms of their respective employment and consultancy agreements. Any options granted are made in accordance with the terms of the Company’s Employee Share and Option Plan (ESOP). The fair value of options granted under employment and consultancy agreements are recognized as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognized over the period during which the employees become unconditionally entitled to the options. The fair value at grant date is determined using a Black-Scholes option pricing model that takes into account the exercise price, the non-tradeable nature of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option. the vesting and performance criteria, the impact of dilution, the term of the option, The fair value of the options granted excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. At each reporting date, the entity revises its estimate of the number of options that are expected to become exercisable. The employee benefit expense recognized each period takes into account the most recent estimate. The impact of the revision to original estimates, if any, is recognized in the statement of profit or loss and other comprehensive in come with a corresponding adjustment to equity. Upon the exercise of options, the balance of the share-based payments reserve relating to those options is transferred to contributed equity. (v) Termination benefits Termination benefits are payable when employment is terminated before the normal retirement date, or when an employee accepts voluntary redundancy in exchange for these benefits. The Company recognises termination benefits when it is demonstrably committed to either terminating the employment of current employees according to a detailed formal plan without possibility of withdrawal or providing termination benefits as a result of an offer made to encourage voluntary redundancy. Benefits falling due more than 12 months after reporting date are discounted to present value. Borrowings Generally, loans and borrowings are initially recognized at cost, being the fair value of the consideration received net of issue costs associated with the borrowing. After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost using the effective interest method. Amortized cost is calculated by taking into account any issue costs and any discount or premium on settlement. The component of the convertible notes that exhibits characteristics of a liability is recognised as a liability in the statement of financial position, net of transaction costs. Convertible notes are initially classified as a financial liability on the amortised cost basis until extinguished on conversion or redemption. Any increase in the liability die to the passage of time is recognised as a finance cost. The corresponding interest on convertible notes is expensed to the statement of profit or loss and other comprehensive income. Contributed equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction from the proceeds. 70 Immuron Limited Notes to the consolidated financial statements 30 June 2017 (continued) 20 Summary of significant accounting policies (continued) (c) Accounting policies (continued) Earnings per share (i) Basic earnings per share Basic earnings per share is calculated by dividing the profit or loss attributable to equity holders of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the full year, adjusted for bonus elements in ordinary shares issued during the full year. (ii) Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. Goods and Services Tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST recoverable or payable. The net amount of GST recoverable from, or payable to, the taxation authorities is included with other receivable or payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flow arising from investing or financing activities which are recoverable for, or payable to, the taxation authorities are presented as operating cash flow. Leases Leases in which a significant portion of the risk and reward of ownership are not transferred to the Company as lessee are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the statement of profit or loss and other comprehensive income on a straight-line basis over the period of the lease. 71 Immuron Limited Directors' declaration 30 June 2017 In the Directors' opinion: (a) the financial statements and notes set out on pages 31 to 71 are in accordance with the Corporations Act 2001, including: (i) (ii) complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements, and giving a true and fair view of the consolidated entity's financial position as at 30 June 2017 and of its performance for the year ended on that date, and there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable, and at the date of this declaration, there are reasonable grounds to believe that the members of the extended closed group will be able to meet any obligations or liabilities to which they are, or may become, subject by virtue of the deed of cross guarantee. (b) (c) Note 20(b) confirms that the financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board. The Directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the Corporations Act 2001. This declaration is made in accordance with a resolution of Directors. Dr. Roger Aston Director Melbourne 28 September 2017 72 The Shareholder information set out below was applicable as at 27 September 2017. A. Distribution of equity securities Analysis of numbers of equity security holders by size of holding: Immuron Limited Shareholder information 30 June 2017 Class of equity security Ordinary shares No. of Holders Total Units 229 430 238 517 168 1,582 58,974 1,317,819 1,892,545 18,901,909 108,269,215 130,440,462 432 463,980 Ordinary shares Number held % 17,999,746 9,360,484 8,624,999 3,665,104 2,907,236 2,731,632 2,645,983 2,500,000 2,000,000 2,000,000 1,700,000 1,624,999 1,425,000 1,421,874 1,334,075 1,331,744 1,127,081 1,000,000 1,000,000 906,000 67,305,957 13.80 7.18 6.61 2.81 2.23 2.09 2.03 1.92 1.53 1.53 1.30 1.25 1.09 1.09 1.02 1.02 0.86 0.77 0.77 0.69 51.59 63,134,505 130,440,462 48.41 100.00 Holding 1 - 1000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Unmarketable parcel B. Equity security holders Twenty largest quoted equity security holders Name HSBC CUSTODY NOM AUST LTD* GRANDLODGE PL* AUTHENTICS AUST PL RETZOS EXECUTIVE PL ANASTASIOU PETER + K P* INVERAREY PL FIFTY-FIFTH LEPRECHAUN PL* INSYNC INV PL SBI INV PR LLC ADVANCE PUBLICITY PL* REED DALE ANTHONY BIDDICK KENNETH + C HAMBLETON STREET PL ADVANCE CLINICAL SYSTEMS PLUSH DAVID A + A L* G & N LORD SUPER PL* CITICORP NOM PL TJS INV AUST PL WESTPARK OPERATIONS PL* BIRD WILLIAM DAVID FRANK Total Total balance of remaining holders Total on issue * Denotes merged holders. 78 B. Equity security holders (continued) Quoted equity securities Immuron Limited Shareholder information 30 June 2017 (continued) No. of Holders Total Units IMCOB listed options exercisable at $0.55 on or before 30 November 2019 362 25,289,894 Unquoted equity securities IMCSO2 unlisted options exercisable at $1.556 on or before 1 November 2016 IMCAC unlisted options exercisable at $0.500 on or before 1 October 2018 IMCAI unlisted options exercisable at $0.570 on or before 24 February 2019 IMCAI unlisted options exercisable at $1.892 on or before 28 February 2019 IMCAI unlisted options exercisable at $0.300 on or before 28 May 2019 IMCAI unlisted options exercisable at $0.500 on or before 27 November 2019 IMCRM1 unlisted options exercisable at $1.944 on or before 30 November 2021 IMCRM2 unlisted options exercisable at $1.876 on or before 17 January 2022 IMCAI unlisted options exercisable at USD$10 for every 40 options on or before 13 June 2022* *Unlisted options held by HSBC Custody Nomination Australia Limited. C. Substantial holders No. of Holders Total Units 1 2 1 1 1 6 1 1 1 62,500 1,050,000 1,000,000 15,380 140,056 7,625,532 14,493 29,668 28,060,000 The name of substantial shareholders the Company is aware of from the register, or who have notified the Company in accordance with Section 671B of the Corporations Act are: HSBC CUSTODY NOM AUST LTD GRANDLODGE PL AUTHENTICS AUST PL D. Shareholder enquiries Number held 17,999,746 15,327,446 8,624,999 41,952,191 Percentage 13.80% 11.75% 6.61% 32.16% Shareholders with enquiries about their shareholdings should contact the Share Register: Security Transfer Registrars PO Box 535, Applecross, WA 6953, Australia Telephone: +61 (0)8 9315 2333 Facsimilie: +61 (0)893152233 E. Change of address, change of name, consolidation of shareholdings Shareholders should contact the Share Registry to obtain details of the procedure required for any of these changes. F. Removal from the Annual Report mailing list Shareholders who wish to receive the Annual Report should advise the Share Registry in writing. These shareholders will continue to receive all other shareholder information. G. Tax File numbers It is important that Australian resident shareholders, including children, have their tax file number or exemption details noted by the Share Registry. 79 Immuron Limited Shareholder information 30 June 2017 (continued) H. CHESS (Clearing House Electronic Sub-Register System) Shareholders wishing to move to uncertified holdings under the Australian Stock Exchange (CHESS) system should contact their stockbroker. I. Uncertified share register Shareholding statement are issued at the end of each month that there is a transaction that alters the balance of your holding. 80 

Continue reading text version or see original annual report in PDF format above